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INTRODUCTION 
 
 
 Gestational diabetes mellitus is defined as any degree of glucose 
intolerance with its onset or first recognition during pregnancy.  
 Early diagnosis of this complication and appropriate treatment aimed at 
tight control over maternal glucose levels may positively influence the 
perinatal outcome.  
There are studies, which suggest platelets play a role in the 
pathogenesis of gestational diabetes mellitus. 
Altered platelet morphology and function have been reported in 
patients with diabetes mellitus (1). These changes may be associated 
with increased risk of vascular disease and venous thromboembolism . 
Although normal pregnancy may result in the activation of primary 
hemostasis and coagulation, these issues have not been widely 
investigated in gestational diabetes. 
Patients with diabetes mellitus show altered platelet function, 
including decreased nitric oxide synthase activity and increased 
peroxynitrite production (2). Platelet volumes are direct indicators of 
increased platelet synthesis (2). In normal pregnancies, a small increase 
in platelet aggregation occurs.  
This increase is compensated for by increased platelet synthesis 
and, consequently, in an increased mean platelet volume (MPV) (3). 
Platelet volume is a marker of platelet function and activation. It can be 
quantified as mean platelet volume (MPV) by clinical hematology 
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analyzers . In a normal pregnancy, changes in platelet volumes may be 
more sensitive than platelet numbers as a measure of altered platelet 
function (4). It is also increased in acute myocardial infarction, acute 
ischemic stroke, pre-eclampsia and renal artery stenosis (5). Importantly, 
an elevated MPV predicts a poor outcome following myocardial 
infarction, restenosis following coronary angioplasty, and the 
development of pre-eclampsia. 
 [6]. It has been proposed that hyperglycemia in diabetic patients 
may lead on to the production of larger platelets .Therefore, the larger 
platelets include denser granules, release more β-thromboglobulin, 
serotonin, and produce more thromboxane A2(7). It is also suggested 
that the increased platelet activity enhances vascular complications in 
these patients. 
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AIM AND OBJECTIVE 
 
 The present study was designed to compare and assess the demographic 
and laboratory findings in healthy pregnant women and Gestational 
diabetes mellitus  patients. . 
 The aim of this study is to compare the various blood parameters 
especially platelet indices  in gestational diabetes and normal pregnant 
women and to investigate whether there is a statistically significant 
difference in these parameters between gestational diabetes mellitus 
patients and in patients with healthy pregnancies . 
 The objective of this study is to highlight the value of inflammatory 
markers  in predicting gestational diabetes mellitus (GDM). 
  This study also evaluates the relationship between blood glucose levels 
and  mean platelet volume. Correlation of blood glucose against Various 
parameters like  HBA1C,Platelet count, mean platelet volume ,Platelet 
distribution width are also studied and results analysed . 
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REVIEW OF LITERATURE 
 
 Pregnancy is a diabetogenic physiologic event. Particularly in late 
gestation, insulin requirements of women with diabetes increase, and 
overt diabetes may develop in women with previously undiagnosed 
glucose intolerance. In others, a transitory asymptomatic impairment in 
glucoregulation may be unmasked.  
 These diabetogenic aspects of pregnancy are associated with maternal 
and fetal complications and may have long-term consequences as well.  
 The fetal complications do not occur when the father is the only diabetic 
parent, and thus they appear to be distinct from the genetic aspects of 
diabetes. They are linked instead to alterations in the maternal 
environment to which the developing conceptus is exposed.  
 The implications for pregnancies in which diabetes mellitus (DM) 
antedates pregnancy (preexisting DM) or is first recognized during the 
present pregnancy (gestational DM [GDM]) are discussed below. 
History  
Before the discovery of insulin, pregnancy in a woman with Diabetes 
Mellitus  was little more than a medical curiosity. The few women with DM 
who survived adolescence were often infertile. Those who conceived 
frequently underwent therapeutic abortion in view of the alarmingly high rates 
of both maternal (25%) and perinatal (40% to 50%) mortality present at the 
time. After therapy with insulin became available, women with diabetes 
generally reached adulthood with little impairment in fertility. Maternal 
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mortality declined to a rate similar to that of women without DM. A 
comparable reduction in fetal wastage did not occur until much later. In the 
1950s and 1960s, pioneering efforts based on the premise that fetal survival is 
linked to control of maternal diabetes reduced the rates of fetal loss to 10% to 
15%. Further improvements followed the development of technologies for 
1. Monitoring the integrity of the fetoplacental unit,  
2. documenting maternal metabolic control more accurately (i.e., self-
monitoring of capillary blood sugar), and  
3. sophisticated management of neonatal morbidity.  
In centers that regularly provide specialized team care to substantial 
numbers of patients, rates of perinatal loss in diabetic pregnancies (except for 
those related to major congenital malformations) now approach those of the 
general obstetric population. Thus attention has increasingly focused on 
neonatal morbidity and the potential effects of maternal diabetes on the 
offspring in later life. 
In recent years, increasing numbers of women with long duration of type 
1 DM are having pregnancies sometimes in the presence of vascular and/or 
neuropathic complications. In the past 2 decades, the prevalence of preexisting 
type 2 DM complicating pregnancy has increased throughout the world. Rates 
of congenital malformations and adverse pregnancy outcome tend to be as high 
as those in pregnancies complicated by type 1 DM.(8) 
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PATHOGENESIS 
Metabolic Effects of Pregnancy  
 The metabolic alterations that develop during pregnancy are profound, 
but they do not occur with equal intensity throughout gestation. Rather, 
a temporal progression is seen in which increasing insulin resistance and 
other metabolic changes parallel the growth of the conceptus.  
 In the immediate postpartum period, the profound insulin resistance 
dissipates rapidly. These metabolic perturbations and their temporal 
associations suggest that they derive from the conceptus.  
 Serial estimates of insulin sensitivity both before and during pregnancy 
in a relatively small number of women with normal carbohydrate 
metabolism indicate a slight reduction in insulin sensitivity by 12 to 14 
weeks and a further decline by the end of the second trimester.(9)  
 During the third trimester, insulin sensitivity is 40% to 60% lower than 
in nongravid women.  (10)  Catalano and colleagues (9)  found modest 
improvement in insulin sensitivity at 12 to 14 weeks in women with 
GDM when compared with their state of insulin resistance before 
pregnancy.  
 This modest improvement was followed by progression to severe insulin 
resistance in late gestation that was equal to or greater than that in 
subjects with normal glucose tolerance.  
 Women with type 1 DM who are in optimal metabolic control before 
conception do not have an increase in insulin requirement during the 
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first trimester and may even require some reduction in dosage because 
of hypoglycemia at the end of the first and beginning of the second 
trimester (11)(Figure 1)     
 
 
Figure -1 
Schematic representation of changing insulin requirements over the course of 
pregnancy and after delivery in pregestational diabetes mellitus. 
( Phelps RL, Metzger BE, Freinkel N: Medical management of diabetes in 
pregnancy. In Sciarra J (ed.): Gynecology and obstetrics, vol 3. Philadelphia: 
Harper & Row; 1988: 1-16.) 
 
 
 In early nondiabetic pregnancies, there is little if any increase in insulin 
secretion in response to glucose. Conversely, insulin secretion in 
response to oral or intravenous glucose in the last trimester of pregnancy 
is approximately 1.5 to 2.5 times greater than that seen in nongravid 
conditions (12) and is accompanied by islet cell hyperplasia.  
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 The product of β-cell secretion is primarily insulin and not a 
disproportionate amount of proinsulin or intermediates, which have 
substantially less activity than insulin.  
 Insulin does not cross the placenta. Although the human placenta is 
small in proportion to total maternal mass, it actively degrades insulin 
and moderately increases insulin clearance in normal pregnancy and 
GDM. (13)(14) 
 These changes occur temporally in parallel .with increasing size of the 
placenta and growth of the fetus. However, the specific mediators of 
increased insulin secretion and insulin resistance are not entirely clear. 
 TABLE 2 lists a number of the many factors potentially implicated in 
these changes.  
 Numerous studies suggest that progesterone, acting either separately or 
in concert with estrogens, has direct β-cell cytotropic actions.  
 Estrogens and their receptors have fundamental actions in the 
hypothalamus, adipose tissue and skeletal muscle, liver, and pancreatic 
beta cells that influence carbohydrate metabolism. (15). When the two sex 
steroids are administered to nonpregnant animals in appropriate molar 
concentration ratios, effects on plasma insulin and fuel storage in liver 
and adipose tissue similar to those seen in normal pregnancy are 
observed without significantly affecting skeletal muscle sensitivity to 
insulin. (16)  
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 Higher circulating concentrations of maternal leptin, potentially of 
placental origin, (17) may reflect the change in insulin sensitivity rather 
than directly contributing to it.  
 During the latter half of pregnancy, circulating levels of human 
chorionic somatomammotropin (hCS) or placental lactogen, estrogen, 
and progesterone reach maximal plasma concentrations with increasing 
placental mass.  
 The concentration of pituitary growth hormone decreases, but the 
increasing level of the growth hormone variant (hGH-V) of placental 
origin may offset the decline. (18) 
 Prolactin also increases throughout gestation and may contribute to the 
insulin resistance.  
 Free cortisol levels increase, but the diurnal variations are maintained 
despite the presence of placental corticotropin and corticotropin-
releasing factor. (19) 
 In recent years, several other factors derived from the placenta and/or 
adipose tissue have been identified as potentially important contributors 
to insulin resistance in normal pregnancy and GDM.  
 These include increases in tumor necrosis factor α (TNF-α) (20) and 
decreases in adiponectin. (21)Several other factors that potentially 
contribute to insulin resistance in type 2 DM have not been fully 
evaluated in normal pregnancy or GDM.  
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TABLE 1 
Factors of Placental Origin that may Influence Maternal Insulin Sensitivity 
Estrogens and progesterone 
Human chorionic somatomammotropin (hCS) or placental lactogen (HPL) 
Prolactin 
Placental growth hormone variant (hGH-V) 
Corticotropin-releasing factor (CRF) and corticotropin 
Leptin 
Tumor necrosis factor α (TNF-α) 
Adiponectin ∗ 
Resistin 
Ghrelin 
Interleukin 6 (IL-6) 
  
Friedman and colleagues concluded that at the molecular level, the 
insulin resistance of normal pregnancy is multifactorial, involving reduced 
ability of insulin to phosphorylate the insulin receptor, decreased expression of 
insulin receptor substrate 1 (IRS-1), and increased levels of a specific kinase. 
(22) Further changes occur in GDM that inhibit signaling and lead to 
substantially reduced GLUT4 translocation.  
The net effect of these combined hormonal and metabolic changes is to 
oppose insulin action at peripheral (muscle and adipose tissue) and hepatic 
sites. 
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Utilization of Maternal Fuels by the Conceptus 
o The placenta is the conduit through which the conceptus continuously 
draws maternal fuel for its metabolic and biosynthetic needs, and 
glucose is the major source of its metabolic energy.  
o In addition, glucose or three-carbon intermediates derived from glucose 
(lactate) are precursors for glycogen, glycoproteins, and the glyceride-
glycerol in triglycerides and phospholipids of the conceptus.  
o Glucose utilization rates as high as 6 mg/kg/minute have been estimated 
in the human fetus at term, (23) in contrast to glucose turnover of 2 to 3 
mg/kg/minute in normal adults. Glucose delivery across the placenta 
occurs by facilitated diffusion, and maternal glucose usually exceeds 
fetal glucose concentration by 10 to 20 mg/dL (0.6 to 1.1 mmol/L). 
o In the third trimester, growth of the human fetus requires the net 
placental transfer of approximately 54 mmol of nitrogen per day. (24) 
Furthermore, amino acids may be used in the conceptus for oxidative 
energy. Although quantitative measurements of nitrogen requirement for 
fetal growth in humans are not available, it is clear that the fetus exerts 
an unremitting drain on maternal nitrogen reserves. 
o Maternal lipid stores, placental fatty acid metabolism and transport, and 
de novo lipogenesis are all sources of fetal lipids. (25) (26). 
o Net transfer of free fatty acids (FFAs) to the fetus is difficult to quantify. 
Glycerol can cross the placenta readily, but its contribution in 
nonruminant mammalian species is probably small. Ketones readily 
12 
 
cross the placenta, are present in the fetal circulation in concentrations 
approaching those in maternal blood, (27) and the enzymes necessary for 
ketone oxidation are present in the human fetus. 
o When fetal tissues, including the brain, are incubated in vitro with 
concentrations of ketones similar to those present during fasting, 
substantial oxidation of ketones is seen, even in the presence of 
alternative fuels (i.e., fasting concentrations of glucose, lactate, and 
amino acids.(27). 
o Oxidation of ketones lessens that of the other fuels and may spare them 
for biosynthetic disposition or other pathways in the fetus. (28) 
o However, such diversion to the metabolism of ketones may have adverse 
consequences. Ketones inhibit pyrimidine and purine synthesis in 
developing brain cells in the rat fetus and at high concentrations disrupt 
organogenesis in rodent embryos in culture.  
o Rizzo and coworkers (29) reported an inverse association between 
increased plasma FFAs and β-hydroxybutyrate concentrations in the 
second and third trimesters of pregnancy and intellectual development of 
offspring at age 2 to 5 years.  
o Recently, Clausen and associates did not find altered cognitive function 
in adult offspring of women with Type 1 diabetes (30) or diet-treated 
GDM (31) to be associated independently with maternal glycemic control 
during pregnancy. 
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CIRCULATIONG CONCENTRATIONS OF NUTRIENT FUELS 
In Normal Pregnancy 
 Normal women have a decrease in the concentration of fasting plasma 
glucose (FPG) during pregnancy.  
 The greatest decline in FPG (10- to 12-hour fast) occurs early in 
gestation, (32) well before the rate of glucose utilization by the fetus is 
sufficient to increase total maternal glucose turnover.  
 It has been reported that obese women do not show a decline of Fasting 
Plasma Glucose  during pregnancy.  
  A lower Fasting plasma Glucose  persists during late gestation despite 
relatively higher postmeal glucose levels.  
However, reports of diurnal glucose profiles of ambulatory 
pregnant women obtained by capillary blood glucose monitoring or 
continuous monitoring of subcutaneous fluid confirm that glycemic 
excursions vary within a narrow range in normal subjects, even during 
late gestation. (33),(34) 
 Basal concentrations of plasma glycerol and FFAs do not change until 
late gestation, at which time significant elevations occur, and transition 
to the metabolic profile characteristic of the fasting state is accelerated 
in association with mounting lipolysis and insulin resistance. (35) 
 Progressive increases occur in all major lipid fractions, including 
triglycerides, cholesterol, and phospholipids.Total plasma amino acid 
concentrations also decline in early pregnancy and persist throughout 
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gestation.  
  In late pregnancy, increased fetal removal, as opposed to impaired 
maternal muscle release of amino acids, may play a primary role in 
sustaining maternal hypoaminoacidemia. 
In Gestational Diabetes Mellitus 
 Basal and postprandial levels of glucose, FFAs, triglycerides, and amino 
acids tend to exceed those of normal pregnant control subjects, (36) and 
the changes tend to persist during dietary intervention, with the extent of 
the abnormalities paralleling the severity of the GDM.  
  Branched-chain amino acids are sensitive to insulin, are often altered in 
obesity and other insulin-resistant states, and are the most consistently 
disturbed.  
  These trends have recently been confirmed in metabolomic assays that 
also provide insight into the metabolic pathways that are involved. (37) 
 The propensity to “accelerated starvation” (e.g., a more rapid decline in 
circulating glucose concentration in association with a greater increase 
in FFAs and ketones) in women with GDM is similar to that found in 
women with normal glucose homeostasis. (38) 
 Diurnal glucose profiles of ambulatory women with diet-treated GDM 
obtained by continuous monitoring of subcutaneous fluid show greater 
glycemic excursions and delay in reaching postprandial peak values than 
seen in normal subjects. 
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 In Women with Preexisting Diabetes Mellitus  
 In pregnant women in whom type 1 DM is well controlled, few 
disturbances in plasma lipids (FFAs, cholesterol, and triglycerides) have 
been found, and individual lipoprotein fractions have little change in 
their lipid content. (39) 
 The greatest departures from the norm during pregnancy occur in 
plasma glucose profiles; plasma amino acid concentrations also may be 
markedly disturbed.  
 Changes in amino acids and indices of glycemic control (blood glucose 
self-monitoring records and hemoglobin A  1c  levels) are poorly 
correlated, especially in late pregnancy.  (40) 
 Lipids tend to be altered more extensively in pregnant women with type 
2 DM, with higher total plasma triglycerides and an increased 
triglyceride content of very low-density lipoproteins.   
 The cholesterol content of high-density lipoproteins may be decreased 
when compared with levels in normal pregnancy or in pregnant women 
with type 1 DM.   
 The relative roles of obesity and diabetes in the development of these 
lipid aberrations remain to be defined. Studies of amino acid metabolism 
in type 2 DM in pregnancy have not been reported.  
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Maternal Metabolism and Pregnancy Outcome  
The pioneering hypothesis advanced by Pedersen  (41 ) stated that 
maternal hyperglycemia leads to fetal hyperinsulinism, which is responsible for 
macrosomia and neonatal morbidity. Extensive experimental and clinical 
evidence indicates that metabolic disturbances in the mother contribute to 
virtually all the adverse effects of DM on the offspring. (42). The importance of 
alterations in other metabolic fuels, in addition to glucose, was recognized 
later.  Results of the HAPO Study   indicate that the associations between 
maternal glycemia, fetal insulin, and parameters of fetal growth extend through 
the full range from “normal” to those that reflect overt diabetes.  
Freinkel  (42) emphasized the temporal relations between a metabolic 
insult and the adverse outcome expected (“fuel-mediated teratogenesis”) and 
postulated that the altered intrauterine environment of diabetes can have 
lifelong as well as perinatal consequences.  
The key features of the hypotheses of Pedersen and Freinkel are 
schematically integrated in  Figure 3   
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FIGURE 2 ILLUSTRATING FREINKEL HYPOTHESIS 
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Table 4  
Age-specific prevalence of non–insulin-dependent diabetes mellitus 
(plasma glucose >200 mg/dL 2 hours after oral glucose) in offspring of Pima 
Indian women without diabetes mellitus  (blue bars),  those developing 
diabetes only subsequent to pregnancy (red bars),  or those with diabetes 
during pregnancy  (green bars).  
(Data from Pettitt DJ, Aleck KA, Baird HR, et al. Congenital susceptibility to 
NIDDM: Role of intrauterine environment.  Diabetes. 1988;37:622-628.)  
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CLASSIFICATION 
Classification  
The ADA(American Diabetes Association) classification of diabetes 
includes four mutually exclusive categories . Three are forms of preexisting 
diabetes (type 1 diabetes, type 2 diabetes, other), and the fourth is gestational 
diabetes.   With modification for pregnancy,    this classification scheme is 
shown in  Table 3    
TABLE 3 - CLASSIFICATION OF DIABETES IN PREGNANCY 
 Type 1 Diabetes.  Diabetes resulting from beta cell destruction, usually leading 
to absolute insulin deficiency  
o •  Without vascular or neuropathic complications  
o •  With complications  
 Type 2 Diabetes  . Diabetes resulting from progressively decreased insulin 
secretion in the face of increased insulin resistance  
o •  Without vascular or neuropathic complications  
o •  With complications  
 Other Types of Diabetes:  Monogenic diabetes, diabetes associated with 
pancreatic disease, drug or chemically induced diabetes, and so forth.  
 Gestational Diabetes:  Diabetes diagnosed during pregnancy that is not clearly 
overt diabetes  
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Classification 
 Pregnant women with either gestational or preexisting diabetes are categorized 
according to the White classification: 12 13 
o Class A1: diabetes diagnosed during pregnancy and controlled by diet 
o Class A2: diabetes diagnosed during pregnancy and requiring medication 
o Class B: insulin-requiring diabetes diagnosed before pregnancy when patient is 
older than 20 years, which lasts fewer than 10 years 
o Class C: insulin-requiring diabetes diagnosed before pregnancy when patient is 
aged 10 to 19 years, which lasts 10 to 19 years 
o Class D: diabetes diagnosed with 1 of the following criteria: patient is older 
than 10 years, diabetes lasts more than 20 years, or diabetes is associated with 
hypertension or background retinopathy 
o Class F: diabetes with renal disease 
o Class H: diabetes with coronary artery disease 
o Class R: diabetes with proliferative retinopathy 
o Class T: diabetes with renal transplant 
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It is recognized that classifying all pregnancies with first recognition or 
diagnosis of hyperglycemia during pregnancy as GDM   includes some women 
with preexisting diabetes. 
Since the treatment during pregnancy and postpartum and perinatal and 
long-term risks for Type 2 DM and GDM differ, the IADPSG Consensus Panel 
that made recommendations for new criteria for GDM also provided guidelines 
for detection and diagnosis of preexisting diabetes.  (44) 
Preexisting Diabetes  
Historically, the White classification of diabetes in pregnancy   was 
devised to predict pregnancy risk in type 1 DM based on age at onset and 
duration of diabetes, in combination with microvascular or macrovascular 
complications. In the present era, fetal loss is less common, and the degree of 
metabolic control throughout pregnancy and the presence or absence of 
vascular complications, independent of maternal age or duration of DM, are 
more specific predictors of maternal or fetal morbidity.  Preexisting diabetes is 
or is not associated with neuropathy or vascular complications.  (45)  Severe 
hypoglycemia and hypoglycemia unawareness are potentially hazardous for 
both mother and fetus.  (46). Therefore these are listed   as complications when 
these events are noted during pregnancy.  
Retinopathy 
Diabetic retinopathy may worsen during gestation. The risk is present 
primarily in women with active proliferative changes or severe preproliferative 
retinopathy. Patients with mild background retinopathy or inactive laser-treated 
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proliferative disease rarely experience progression of consequence. An 
association has been found between worsening retinopathy during pregnancy 
and the severity of hyperglycemia at enrollment  (47) (48)and the magnitude of 
improved glycemic control achieved in the first half of gestation.  This 
worsening during pregnancy may be analogous to the transient deterioration 
observed in nonpregnant subjects after the initiation of “tight” control of 
diabetes.  
Data from the Diabetes Control and Complications Trial (49)  indicate 
that pregnancy per se adds independently to the risk for transient progression of 
retinopathy, and the increased risk for progression may continue during the first 
postpartum year. Hypertension in pregnancy also is associated with progression 
of diabetic retinopathy.  (50)  .Regardless of the mechanisms involved, women 
with preexisting retinopathy should be advised of the potential for deterioration 
and the need for close ophthalmologic follow-up before conception, during 
pregnancy, and in the postpartum period. Although photocoagulation therapy 
can be used effectively during gestation, those with active proliferative disease 
should be advised to postpone pregnancy until photocoagulation treatment has 
stabilized the retinal condition.  
Nephropathy  
Diabetic nephropathy (24-hour urine protein ≥0.5 g or reduced 
creatinine clearance) increases risks for both the mother and 
offspring.   Worsening proteinuria (twofold to threefold increase), 
hypertension, premature labor, and a need for early induction are common 
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outcomes. The risks for these complications increase with stage of nephropathy 
(Table 4). 
Most women experience little permanent effect on renal function, 
despite transient but substantial increases in proteinuria.  (49)(50).  Occasionally, 
patients experience deterioration in renal function that continues in the 
postpartum period.  Whether this decline is related to pregnancy or reflects the 
natural progression of renal impairment is uncertain. The number of subjects 
with severe diabetic nephropathy is too small to gain definitive information at 
any single center.   
TABLE 4 
Stages of the Evolution of Diabetic Nephropathy and Common Effects on 
Pregnancy 
Stages of diabetic 
nephropathy 
Hyperfiltration  
GFR 
ml/min 
≥150  
Proteinuria  
mg/dl 
30 mg/dl 
Maternal and foetal 
consequences 
Unknown  
Microalbuminuria  ≥90  30-299 mg/dl Increased preeclampsia  
Macroalbuminuria  ≥90  ≥300 mg/dl Increased preeclampsia  
Early nephropathy  60-89  ≥500 mg/dl Fetal growth restriction  
Moderate CKD  30-59  Massive 
proteinuria  
Poor perinatal outcome  
Severe CKD  15-29  Less proteinuria  Delay pregnancy until 
posttransplant  
Renal failure  <15   Dialysis  
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Neuropathy  
Diabetic neuropathy is commonly found in patients with long-standing 
diabetes. Little is known about the effect of pregnancy on progression of 
diabetic neuropathy. However, autonomic neuropathy may contribute to 
maternal morbidity and adverse pregnancy outcomes(52).  Gastroparesis may 
result in marked glucose lability, inadequate nutrition, and maternal pulmonary 
aspiration. Bladder dysfunction may increase the risk for urinary tract infection 
and worsening renal function.  
Cardiovascular Disease  
Both systolic and diastolic blood pressure may increase in pregnancy in 
type 1 diabetic women.    In dated studies, myocardial infarction was associated 
with a 50% mortality.  (53)  An increased risk for myocardial infarction and 
congestive heart failure is also found in the postpartum period.  
The number of subjects with either long-standing type 1 or type 2 DM 
who experience coronary artery disease during pregnancy is small. At this time, 
an efficient, cost-effective strategy for detection and treatment of 
cardiovascular disease before and during pregnancy is not available.   
Haemostasis 
The abnormal metabolic state that accompanies diabetes renders arteries 
susceptible to atherosclerotic complications being capable of altering the 
functional properties of multiple cell types, including endothelium and 
platelets.  
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In particular, an altered platelet metabolism and changes in intraplatelet 
signaling pathways may contribute to the pathogenesis of vascular 
complications of diabetes.  
A variety of mechanisms may be responsible for enhanced platelet 
aggregation. Among them, hyperglycemia may represent a causal factor for in 
vivo platelet activation, and may be responsible for  non enzymatic glycation of 
platelet glycoproteins, causing changes in their structure and conformation, 
evidenced by an increase in mean platelet volume measured in automated CBC 
coulter machine .There is also  alteration of membrane lipid dynamics that 
takes place . 
Furthermore, hyperglycemia-induced oxidative stress is responsible for 
enhanced peroxidation of arachidonic acid to form biologically active 
isoprostanes, which represents an important biochemical link between impaired 
glycemic control and persistent platelet activation.  
Finally, increased oxidative stress is responsible for activation of 
transcription factors and expression of redox-sensitive genes leading to a 
phenotypic switch of endothelium toward an adhesive, pro-thrombotic 
condition, initial platelet activation, adhesion and subsequent platelet aggregate 
formation. Attention to appropriate medical management of diabetic patients 
will have great impact on long-term outcome in this high-risk population. 
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Fig 3 - Picture of a Peripheral smear illustrating giant platelets 
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DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS 
Criteria for the diagnosis of GDM were initially proposed 50 years 
ago.    The National Diabetes Data Group (NDDG)  (54) and the World Health 
Organization (WHO) (55) made recommendations for the diagnosis of GDM 
about 35 years ago. Both the American Diabetes Association   and the 
American College of Obstetricians and Gynecologists(56)   recommended 
strategies for GDM detection and diagnosis nearly 30 years ago. 
However, throughout the last half century, there has been controversy 
about the value of this effort. One point of contention has been lack of 
conclusive evidence that in GDM the “diabetic fetopathy–like” outcomes are 
independently linked to maternal glycemia rather than phenotypic 
characteristics (e.g., obesity, higher maternal age, chronic hypertension). The 
second issue has been lack of evidence from randomized controlled trials that 
the treatment of mild GDM is effective. As recently as 2008, The United States 
Preventive Services Task Force (USPSTF) concluded that “current evidence is 
insufficient to assess the balance of benefits and harms of screening for 
gestational diabetes mellitus, either before or after 24 weeks’ gestation.”  
 
 
 
 
 
28 
 
RECOMMENDATIONS OF NATIONAL AND INTERNATIONAL 
ORGANIZATIONS   
The optimum strategy for diagnosis of gestational diabetes mellitus to 
improve maternal and infant health is unclear (57). Many organizations have 
published recommendations for screening and diagnosis of diabetes in 
pregnancy, including: 
 American College of Obstetricians and Gynecologists (ACOG, two-step 
approach  
 International Association of Diabetes and Pregnancy Study 
Groups (IADPSG, one-step approach ) 
 American Diabetes Association (ADA, one-step or two-step approach)  
 World Health Organization (WHO, one-step approach  
 Canadian Diabetes Association (CDA, two-step [preferred] or one-step 
approach)  
 The Endocrine Society (one-step approach)  
 Australasian Diabetes in Pregnancy Society (WHO approach)  
 National Institute for Health and Care Excellence (NICE, United 
Kingdom) 
 International Federation of Gynecology and Obstetrics (FIGO), 
IADPSG (one-step approach, with possible variation in economically 
challenged regions)  
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The O’Sullivan and Mahan criteria for the diagnosis of GDM,    initially 
established 50 years ago, with minor modifications remain in widespread use 
today, particularly in North America. These criteria were chosen to identify 
women at high risk for development of diabetes following pregnancy, not to 
identify pregnancies at increased risk for adverse perinatal outcomes.  
The World Health Organization (WHO) recommended criteria for GDM 
that are the same as those used to classify glucose tolerance in nonpregnant 
persons.  When the National Diabetes Data Group (NDDG) developed the 
classification and diagnosis of DM in 1979,   the AutoAnalyzer colorimetric 
(ferricyanide-based) analytic method for glucose was the “gold standard.”  
Currently, glucose assays are primarily enzymatic (glucose oxidase or 
hexokinase). Carpenter and Coustan  (58)  derived values for interpretation of a 
100-g OGTT that more accurately extrapolates the O’Sullivan results to 
glucose oxidase-based methods. This results in lower plasma glucose values for 
the diagnosis of GDM than those recommended by the NDDG and about a 
50% increase in the number of women with a diagnosis of GDM.   
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Table 5 
Screening for Gestational Diabetes (GDM) 
Pregnant women with risk factors Test for undiagnosed type 2 at first 
prenatal visit using standard 
diagnostic criteria 
Pregnant women without known 
prior diabetes 
Test for GDM at 24-28 weeks 
Women with GDM Screen for persistent diabetes 6-12 
wks postpartum using OGTT and 
standard diagnostic criteria 
Women with a history of GDM Lifelong screening for diabetes or 
prediabetes every ≥3 yrs 
Women with a history of GDM 
and prediabetes 
Lifestyle interventions or 
metformin for diabetes prevention 
 Women with diabetes in the first trimester have type 2 diabetes 
 GDM is diagnosed in the second or third trimester and not clearly 
associated with type 1 or type 2 diabetes  
Screening is recommended at 24-48 weeks in women 
who were not previously diagnosed with overt diabetes using either the 
one step or the two  step strategy 
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TABLE 6 
Strategy for Detection and Diagnosis of Hyperglycemic Disorders in 
Pregnancy 
 
IADPSG and ADA criteria ( ONE STEP STRATEGY) 
Two hour 75-gram oral glucose tolerance test  
Fasting ≥92 mg/dL (5.1 mmol/L) 
OR 
One-hour ≥180 mg/dL (10.0 mmol/L) 
OR 
Two-hour ≥153 mg/dL (8.5 mmol/L) 
 
The diagnosis of gestational diabetes is made at 24 to 28 weeks of 
gestation when one or more plasma glucose values meets or exceeds the above 
values.  
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Table 7 
ACOG TWO STEP STRATEGY 
Step one 
1. Give 50-gram oral glucose load without regard to time of day 
2. Measure plasma or serum glucose 
3. Glucose ≥135 mg/dL (7.5 mmol/L) or ≥140 mg/dL (7.8 mmol/L) is elevated 
and requires administration of a 100-gram oral glucose tolerance test*. The 
lower threshold provides greater sensitivity, but would result in more false 
positives and would require administering the full glucose tolerance test to 
more patients than the 140 mg/dL threshold. The lower threshold should be 
considered in populations with higher prevalence of gestational diabetes.  
Step two 
1. Measure fasting serum or plasma glucose concentration 
2. Give 100-gram oral glucose load 
3. Measure plasma or serum glucose at one, two, and three hours after glucose 
load 
4. A positive test is generally defined by elevated glucose concentrations at two 
or more time points (either Carpenter and Coustan thresholds or National 
Diabetes Data Group thresholds can be used).  
 In 2017, ACOG stated that even one abnormal value may be used for the 
diagnosis of GDM. 
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Table 8 
Diagnostic criteria for the 100-gram three-hour GTT to diagnose 
gestational diabetes mellitus 
  
Plasma or serum glucose level 
Carpenter/Coustan 
Plasma level 
National Diabetes Data Group 
mg/dL mmol/L mg/dL mmol/L 
Fasting 95 5.3 105 5.8 
One hour 180 10.0 190 10.6 
Two hours 155 8.6 165 9.2 
Three hours 140 7.8 145 8.0 
 
 100-gram oral glucose load is given in the morning to a patient who has 
fasted overnight for at least 8 hours but not more than 14 hrs and after 
atleast 3 days of unrestricted diet and physical activity . 
 Glucose concentration greater than or equal to these values at two or 
more time points are generally considered a positive test, but in 2017 an 
American College of Obstetricians and Gynecologists practice bulletin 
stated that clinicians may reasonably consider one elevated 
value diagnostic of a positive test  
 Two different classification schemes of GDM based upon results of the 
three-hour GTT results have been proposed. 
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The diagnostic criteria for GDM that were proposed by O’Sullivan and 
Mahan in 1964   were selected to identify pregnant women at risk for 
subsequent risk for diabetes mellitus outside of pregnancy. The thresholds 
Table 10  that were selected (mean +2 SD) for each value in the OGTT meant 
that the frequency of GDM in that cohort would be low and similar to that of 
diabetic . 
Wilkerson and O’Sullivan (59) compared the use of “risk factor” and 
blood glucose testing with the 50-gram, 1-hour glucose challenge test 
(GCT).    Glucose testing proved to be more sensitive and specific and later 
lead to identification of a GCT (60) threshold that identified 79% of those with 
GDM.   
The optimal cost-effective strategy for the detection and diagnosis of 
GDM has been the subject of much controversy for decades. In the United 
States and a number of other countries, the standard procedure has been to do a 
screening 50-gm GCT at 24 to 28 weeks of gestation followed by a 3-hour 
OGTT in those with a positive GCT.   In some other countries, an OGTT is 
performed as the only blood glucose test in women with a history of GDM risk 
factors. In our centre we usually follow a 100 gm GCT according to DIPSI 
criteria. 
However, in a recent systematic review, van Leeuwen and 
associates  (60)  found that although the GCT leads to the identification of only 
75% to 80% of GDM in a cohort, it remains an acceptable screening test and 
superior to risk-factor–based screening. This approach to the detection of GDM 
35 
 
is likely to remain in use by those that continue to follow ACOG 
recommendations.   The lower diagnostic thresholds recommended by the 
IADPSG    and the diagnosis of GDM with one or more values equal to or 
exceeding a diagnostic threshold yields a substantially higher frequency of 
GDM.    A two-step diagnostic strategy is not more cost-effective than a one-
step approach when the frequency of GDM is high(61)  .Furthermore, use of the 
GCT to detect GDM based on the IADPSG recommendations    has not been 
reported, and its use does not take into consideration the strong association of 
fasting glucose and perinatal outcomes that was found in the HAPO Study. 
It is important that glucose measurements on serum or plasma be made 
with certified laboratory techniques. Although measurement of capillary blood 
glucose with portable meters and reagent strips is convenient and rapid, a 
within-test variability of 10% to 15% markedly reduces both the sensitivity and 
specificity of this approach.  Measurements of random blood 
glucose, (62)   hemoglobin A  1c  (63)(64)  or fructosamine(65)    also are not 
sufficiently sensitive for screening purposes.   
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CONSEQUENCES OF GDM  
In addition to routine pregnancy issues, the prenatal care of women with 
gestational diabetes mellitus (GDM) focuses upon identifying and managing 
conditions that are more common among women with glucose impairment. In 
contrast to women with pregestational diabetes, women with true GDM 
typically do not have diabetes-related vasculopathy or an increased risk of 
infants with congenital malformations because of the short duration of the 
disorder and late pregnancy onset. 
Short-term — Complications of pregnancy more common in GDM include: 
 Large for gestational age (LGA) infant and macrosomia – LGA and 
macrosomia are the most common adverse neonatal outcomes associated 
with GDM. A prospective cohort study observed that accelerated fetal 
growth may begin as early as 20 to 28 weeks of gestation (66). 
Randomized trials have consistently demonstrated that maternal 
hyperglycemia significantly increases a woman's chances of having a 
macrosomic or LGA infant (67)and excessive maternal weight gain (>40 
lbs [18 kg]) doubles the risk.(68) Macrosomia, in turn, is associated with 
an increased risk of operative delivery (cesarean or instrumental vaginal) 
and adverse neonatal outcomes, such as shoulder dystocia and its 
associated complications: brachial plexus injury, fracture, and neonatal 
depression.Truncal asymmetry (disproportion in the ratio of the size of 
the shoulder or abdomen-to-head) in infants of diabetic mothers also 
appears to increase the risk 
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 Preeclampsia – Women with GDM are at higher risk of developing 
preeclampsia than women without GDM. Insulin resistance is the cause 
of GDM and also appears to be associated with development of 
preeclampsia, which may account for this finding(69)(70) A significant 
association (OR 1.3-3.1) between midtrimester insulin resistance and 
development of preeclampsia has been reported in several studies, even 
in the absence of GDM (71)(72) 
 Polyhydramnios – Polyhydramnios is more common in women with 
GDM. The etiology in GDM is unclear, although a contribution from 
fetal polyuria has been suggested. Its impact in GDM versus non-GDM 
pregnancies is also uncertain. Two studies reported GDM-related 
polyhydramnios did not significantly increase perinatal morbidity or 
mortality (73) while a third study reported a markedly increased risk of 
stillbirth in all nonanomalous pregnancies with polyhydramnios, 
whether or not also complicated by GDM. 
 Stillbirth – GDM is associated with a higher risk of stillbirth (74)(75). This 
risk appears to be related primarily to poor glycemic control and does 
not appear to be increased compared with the general obstetrical 
population in women with good glycemic control, though ascertainment 
of such control can be challenging 
 Neonatal morbidity – Neonates of pregnancies complicated by GDM 
are at increased risk of multiple, often transient, morbidities, including 
hypoglycemia, hyperbilirubinemia, hypocalcemia, hypomagnesemia, 
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polycythemia, respiratory distress, and/or cardiomyopathy(74) .These 
risks are related, in large part, to maternal hyperglycemia. 
 Long-term — Risks associated with GDM extend beyond the 
pregnancy and neonatal period. GDM may affect the offspring's risk of 
developing obesity, impaired glucose tolerance, or metabolic syndrome . 
GDM is also a strong marker for maternal development of type 2 
diabetes, including diabetes-related vascular disease. 
FETAL EFFECTS — Poor glycemic control in pregnant diabetic women 
leads to deleterious fetal effects throughout pregnancy, as follows  
 In the first trimester and time of conception, maternal hyperglycemia 
can cause diabetic embryopathy resulting in major birth defects and 
spontaneous abortions. This primarily occurs in pregnancies with 
pregestational diabetes. The risk for congenital malformations is only 
slightly increased with gestational diabetes mellitus (GDM) compared 
with the general population (odds ratio [OR] 1.1-1.3). The risk of 
malformations increases as maternal fasting blood glucose levels and 
body mass index (BMI) increases when GDM is diagnosed early in 
pregnancy. These findings suggest that some of these mothers are 
probably undiagnosed women with type 2 diabetes  
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●Diabetic fetopathy occurs in the second and third trimesters, resulting in 
fetal hyperglycemia, hyperinsulinemia, and macrosomia. 
 Animal studies have shown that chronic fetal hyperinsulinemia results 
in elevated metabolic rates that lead to increased oxygen consumption 
and fetal hypoxemia, as the placenta may be unable to meet the 
increased metabolic demands. 
 Fetal hypoxemia contributes to increased mortality, metabolic 
acidosis, alterations in fetal iron distribution, and increased 
erythropoiesis (75). Increased synthesis of erythropoietin leads to 
polycythemia (76)(77) ;promotes catecholamine production, which can 
result in hypertension and cardiac hypertrophy; and may contribute to 
the 20 to 30 percent rate of stillbirth seen in poorly controlled diabetic 
pregnancies.  
 As the fetal red cell mass increases, iron redistribution results in iron 
deficiency in developing organs, which may contribute to 
cardiomyopathy and altered neurodevelopmen( Fetal hyperinsulinemia 
is also thought to contribute to impaired or delayed lung maturation. 
 Oxidative stress may play a role in maternal and fetal complications of 
diabetic pregnancies. For example, increased generation of reactive 
oxygen species with inadequate antioxidant defenses in the fetal heart 
might lead to abnormal cardiac remodeling and hypertrophic 
cardiomyopathy(78) .In addition, increased erythropoietin production 
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with resultant polycythemia in the newborn infant of a diabetic mother 
(IDM) was related to the degree of oxidative stress. 
 Excessive nutrients delivered from the poorly controlled diabetic 
mother cause increased fetal growth, particularly of insulin-sensitive 
tissues (ie, liver, muscle, cardiac muscle, and subcutaneous fat), 
resulting in macrosomia, defined as a birth weight (BW) ≥4000 g or 
greater than the 90th percentile for gestational age (GA)  
 Maternal hyperglycemia leads to fetal hyperglycemia resulting in fetal 
hyperinsulinemia and neonatal hypoglycemia. Fetal hyperinsulinemia 
also stimulates storage of glycogen in the liver, increased activity of 
hepatic enzymes involved in lipid synthesis, and accumulation of fat in 
adipose tissue. These metabolic effects might contribute to long-term 
metabolic complications in the offspring.  
 
NEONATAL EFFECTS — IDMs are at increased risk for mortality and 
morbidity compared with neonates born to a nondiabetic mother . 
Neonatal complications in offspring of diabetic mothers include: 
I. Congenital anomalies 
II. Prematurity 
III. Perinatal asphyxia 
IV. Macrosomia, which increases the risk of birth injury (eg, brachial 
plexus injury) 
V. Respiratory distress 
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VI. Metabolic complications including hypoglycemia and 
hypocalcemia 
VII. Hematologic complications including polycythemia and 
hyperviscosity 
VIII. Low iron stores 
IX. Hyperbilirubinemia 
X. Cardiomyopathy 
The magnitude of the effect of diabetes during pregnancy was 
demonstrated by a case series of 530 infants born to mothers with gestational 
diabetes and 177 mothers with insulin-dependent diabetes from 1994 to 1996. 
The following findings and their relative frequency were observed: 
 Large for gestational age (LGA), defined as birth weight (BW) greater 
than the 90th percentile  --(36 percent) 
 Prematurity (36 percent): 14 percent with gestational age (GA) <34 
weeks and 22 percent with GA between 34 and 37 weeks 
 Respiratory distress      -- (34 percent) 
 Hyperbilirubinemia      ---  (25 percent) 
 Polycythemia                --- (5 percent) 
 Congenital anomalies    --- ( 5 percent) 
1. Congenital anomalies — IDMs are at a significant risk for major 
congenital anomalies due to maternal hyperglycemia at the time of 
conception and during early gestation .  
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2. The overall reported risk for major malformations is about 5 to 6 
percent with a higher prevalence rate of 10 to 12 percent when 
mothers require insulin therapy.(78)(79)(80). 
3. Congenital malformations account for approximately 50 percent of 
the perinatal deaths in IDMs . 
4. Among women with overt diabetes before conception, the risk of a 
structural anomaly in the fetus is increased threefold to eightfold, 
compared with the 1% to 2% risk for the general population. 
5. This risk can be reduced by strict glycemic control during the pre- 
and periconceptual (first eight weeks of pregnancy) period. 
PATHOGENESIS OF DIABETIC EMBRYOPATHY 
 The mechanism by which hyperglycemia disturbs embryonic 
development is multifactorial. The glucose transporter GLUT2 plays a 
prominent role in mediating embryonic glucotoxicity. (82) 
 A variety of environmental changes with teratologic consequences for 
diabetic embryopathy have been identified.  
 Diabetic teratogenesis has been associated with oxidative stress,  
enhanced lipid peroxidation, decreased antioxidative defense capacity, 
and sorbitol accumulation.  Along these lines, high doses of vitamins C 
and E decreased fetal dysmorphogenesis to nondiabetic levels in vivo 
and in rat embryo culture.  
 Likewise, addition of prostaglandin inhibitors to cultures of mouse 
embryos prevented glucose-induced embryopathy.  The underlying 
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biochemical and molecular mechanisms of diabetic embryopathy have 
started to be deciphered.  Disturbed arachidonic acid metabolism, 
alteration in activity of protein kinase C, increased apoptosis,  and 
enhanced JNK1 and JNK2 activity have been well documented. 
Decreased expression of the gene PAX3 is central to the appearance of 
neural tube defects. Recent studies have indicated that the detrimental 
effect of PAX3 in embryos during a diabetic pregnancy are mediated by 
adenosine monophosphate−activated protein kinase (AMPK) signaling 
pathways.  
TABLE 9 LIST OF CONGENITAL ANOMALIES WITH ITS 
FREQUENCY OF OCCURANCE IN INFANTS OF DIABETIC 
MOTHERS 
ANOMALY APPROXIMATE 
RELATIVE RISK 
PERCENT RISK  
All cardiac defects  18 8.5% 
CNS Anomalies 16 5.3% 
Anencephaly  13  
Spina bifida  20  
All congenital anomalies 8 18.4% 
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TABLE 10 
Common congenital anomalies in infants of diabetic mothers 
System Manifestations 
Neurologic Anencephaly with or without herniation of neural elements, 
arrhinencephaly, microcephaly, holoprosencephaly, neural tube 
defects (meningomyelocele and other variants). 
Cardiovascular Transposition of the great vessels with or without ventricular 
septal defect (VSD), VSD, coarctation of the aorta with or 
without VSD or patent ductus arteriosus, atrial septal defect, 
single ventricle, hypoplastic left ventricle, pulmonic stenosis, 
pulmonary valve atresia, double outlet right ventricle truncus 
arteriosus. 
Gastrointestinal Duodenal atresia, imperforate anus, anorectal atresia, small left 
colon syndrome, situs inversus. 
Genitourinary Ureteral duplication, renal agenesis, hydronephrosis. 
Skeletal Caudal regression syndrome (sacral agenesis), hemivertebrae. 
Other Single umbilical artery. 
 
There is no increase in birth defects among offspring of diabetic fathers 
and nondiabetic women or in women who develop GDM after the first 
trimester, indicating that glycemic control during embryogenesis is the main 
factor in the genesis of diabetes-associated birth defects.  
1. A classic report by Miller (80) and associates compared the frequency of 
congenital anomalies in patients with normal or high first-trimester 
maternal glycohemoglobin levels and found only a 3.4% rate of anomalies 
with an Hb A 1C value lower than 8.5%, whereas the rate of malformations 
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in patients with poorer glycemic control in the periconceptional period (Hb 
A 1C >8.5%) was 22.4%. 
2. Preterm delivery — Spontaneous and medically indicated preterm 
delivery occur more frequently in diabetic than nondiabetic pregnancies 
3. Perinatal asphyxia — IDMs are at increased risk for intrauterine or   
perinatal asphyxia due to macrosomia (failure to progress and shoulder 
dystocia) and cardiomyopathy (fetal heart rate abnormalities), which often 
is defined broadly in the literature to include fetal heart rate abnormalities 
during labor, low Apgar scores , and intrauterine death. Perinatal asphyxia 
correlated with hyperglycemia in labor, prematurity, and nephropathy. 
Maternal vascular disease, manifested by nephropathy, may contribute to 
the development of fetal hypoxia and subsequent perinatal asphyxia. 
4. Macrosomia — Macrosomia, defined as BW greater than the 
90th percentile on a population-appropriate growth chart or above 4000 g, 
is a common complication in IDMs.  
5. Macrosomia can occur in all diabetic pregnancies, but the incidence 
appears to be greater in infants born to mothers with pregestational 
diabetes. 
6. IDMs with macrosomia are more likely than those who are not 
macrosomic to have hyperbilirubinemia, hypoglycemia, acidosis, 
respiratory distress, shoulder dystocia, and brachial plexus injury 
7. Macrosomia is associated with disproportionate growth, resulting in an 
increased ponderal index that results in higher chest-to-head and shoulder-
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to-head ratio, higher body fat, and thicker upper extremity skinfolds 
compared with nondiabetic control infants of similar weight and length(81) 
8. As a result, at birth, IDMs typically appear large and plethoric, with 
excessive fat accumulation in the abdominal and scapular regions, and 
have visceromegaly 
9. LGA infants born to mothers with gestational diabetes were more likely to 
have disproportionate macrosomia than LGA infants of nondiabetic 
mothers (44 versus 36 percent) (82) 
 
 
 
 
Fig 4 Illustrating a Macrosomic Baby Born to a Mother with GDM 
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5)Birth injury 
 Macrosomia predisposes to birth injury, especially shoulder dystocia. 
Shoulder dystocia occurs in nearly one-third of IDMs with macrosomia 
and is associated with increased risk of brachial plexus injury, clavicular 
or humeral fractures, perinatal asphyxia, and, less often, 
cephalohematoma, subdural hemorrhage, or facial palsy. 
 The risk of shoulder dystocia is also increased by the disproportionate 
growth that occurs in macrosomic IDMs, resulting in a higher chest-to-
head and shoulder-to-head ratio than infants of nondiabetic mothers . 
. 
6) Respiratory distress — Respiratory distress is a common complication in 
IDMs, primarily due to the increased risk of neonatal respiratory distress 
syndrome (RDS) due to surfactant deficiency. 
Respiratory distress syndrome — RDS due to surfactant deficiency occurs 
more frequently in IDMs for the following two reasons. 
 IDMs are more likely to be delivered prematurely than infants born to 
nondiabetic mothers.  
 At a given gestational age, IDMs are more likely to develop RDS 
because maternal hyperglycemia appears to delay surfactant synthesis. 
The proposed underlying mechanism is neonatal hyperinsulinemia, 
which interferes with the induction of lung maturation by 
glucocorticoids. 
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 Other causes of respiratory distress — In addition to RDS, other 
causes of respiratory distress in IDMs include transient tachypnea of the 
newborn (TTN) and cardiomyopathy.  
TTN occurs two to three times more commonly in IDMs than in normal infants 
7) Metabolic complications — IDMs are at increased risk for metabolic 
complications in the newborn period. The most common are hypoglycemia, 
hypocalcemia, and hypomagnesemia. 
a)  Hypoglycemia — Hypoglycemia, defined as blood glucose levels below 
40 mg/dL (2.2 mmol/L) in the first 24 hours of life, occurs frequently in IDMs. 
 The onset of hypoglycemia typically occurs within the first few hours 
after birth.  
  Further testing should be undertaken to define the cause of persistent 
hypoglycemia in infants who continue to require glucose infusions at 
rates exceeding 8 to 10 mg/kg per minute to maintain normal plasma 
glucose levels beyond the first week of life. 
b)  Hypocalcemia — The reported prevalence of hypocalcemia, defined as a 
total serum calcium concentration less than 7 mg/dL (1.8 mmol/L) or an 
ionized calcium value less than 4 mg/dL (1 mmol/L). 
 Good glycemic control during pregnancy reduces the risk of neonatal 
hypocalcemia (82) 
 Hypocalcemia in term IDMs usually is asymptomatic and resolves 
without treatment . As a result, routine screening is not recommended.  
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c) Hypomagnesemia — Hypomagnesemia, defined as serum magnesium 
concentration less than 1.5 mg/dL (0.75 mmol/L), occurs in up to 40 percent of 
IDMs within the first three days after birth . It has been proposed that low 
neonatal levels are due to maternal hypomagnesemia caused by increased 
urinary loss secondary to diabetes.  
8)  Polycythemia and hyperviscosity syndrome — Elevated hematocrits 
including polycythemia, defined as a central venous hematocrit of more 
than 65 percent, are more likely in IDMs than in infants born to nondiabetic 
mothers. 
 Higher hemoglobin and hematocrit values in the newborn are associated 
with fetal exposure to oxidative stress (83). 
9) Low iron store — The combined erythrocyte and storage iron pools are 
lower in infants of diabetic mothers . 
10)Hyperbilirubinemia — Hyperbilirubinemia occurs in 11 to 29 percent 
of IDMs.  
 11)Cardiomyopathy — IDMs are at increased risk for transient 
hypertrophic cardiomyopathy(84) . 
 In this condition, the most prominent change is thickening of the 
interventricular septum (IVS) with reduction in the size of the 
ventricular chambers, resulting in potential obstructed left ventricular 
outflow.  
. 
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LONG-TERM OUTCOME — Long-term outcome data show that prenatal 
exposure to hyperglycemia increases the risk of postnatal metabolic 
complications like diabetes mellitus and impacts neurodevelopmental outcome 
especially cognitive development. 
Treatment of Gestational Diabetes Mellitus 
Metabolic Management  
Goals  
 The rationale for treatment of GDM has been summarized earlier and 
supported by various randomized control trials. 
 Restoration of fasting and postmeal glucose values to within normal 
ranges is the primary goal of treating GDM, with the initial step being 
lifestyle modification.  
 Although controlled trials have not been performed to identify ideal 
glycemic targets for the prevention of fetal risk, evidence presented at 
the Fourth International Workshop Conference on Gestational Diabetes 
Mellitus suggests that reducing maternal capillary blood glucose 
concentrations to 140 mg/dL or less (7.8 mmol/L) at 1 hour, or 120 
mg/dL or less (6.7 mmol/L) 2 hours after meals, or both, may reduce the 
risk for excessive fetal growth.   
 The target for fasting and premeal values is commonly less than 95 
mg/dL (5.3 mmol/L). Recent studies in normal pregnant women have 
found blood glucose levels lower than previously expected, with mean 
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glucose concentration 78.3 mg/dL at 38 weeks and mean postprandial 
glucose values not exceeding 105.2 mg/dL at 1 or 2 hours.  
  Even in these nondiabetic women, maternal postprandial capillary 
glucose measurements correlated with fetal size (abdominal 
circumference).   
Some investigators have provided evidence that it is more cost-effective 
to assess fetal abdominal circumference 
Lifestyle Modification  
Nutritional Therapy  
o Medical nutrition therapy (MNT) is referred to as the “cornerstone” of 
medical or metabolic management of GDM.  
o The objectives of MNT and the approaches used for GDM are the same 
as already discussed for normal pregnancy and preexisting DM.  
o Adjustments are made to the initial prescription (35 to 38 kcal/kg IBW 
[145 to 160 kJ/kg]) as needed to maintain weight gain within the range 
appropriate for the subject’s prepregnancy weight.  
o   Several “isocaloric” modifications of the standard diet have been 
investigated. Reduction in carbohydrate content to 30% to 40% can 
reduce postprandial hyperglycemia (85) but is associated with an 
increased fat or protein content, or both.  
o The effects on maternal amino acid, ketone, and lipid levels and on 
long-term outcomes for the offspring are not known. When the daily 
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dietary intake is ingested as multiple small meals (six or seven), 
postprandial glycemic peaks are reduced.   
o However, fasting levels may not be achieved before the next meal, and 
mean 24-hour glucose may not differ from the standard approach (three 
meals plus bedtime snack).  
o Safety, efficacy, and long-term outcomes need further study. 
o  Foods with a low glycemic index and fiber-enriched diets have been 
evaluated for both prevention and treatment of GDM.   Convincing 
evidence of effectiveness is lacking.  
Hypocaloric Diet  
o Because caloric restriction in obese nonpregnant subjects with type 2 
DM can reduce insulin resistance and correct hyperglycemia, use of a 
hypocaloric diet in obese women with GDM is appealing.  
o Moderate caloric restriction (25% to 35% below standard diets) results 
in some correction of hyperglycemia.  (86) 
o Some     groups have noted a reduction in fetal weight in these subjects; 
however, larger numbers in controlled trials are needed to evaluate 
immediate and long-term safety and efficacy of this approach.  
o Knopp and associates  (86)  also examined metabolic responses to a more 
severe (50%) reduction in caloric intake in obese women with GDM.  
o Mean 24-hour glucose, fasting insulin, and triglyceride levels declined 
substantially, but plasma β-hydroxybutyrate concentrations increased 
more than twofold, and ketonuria increased significantly.            
53 
 
o Until more data are available on the effects of such treatment on 
perinatal and long-term outcomes, caloric restriction of this magnitude 
should be considered experimental. Monitoring plasma β-
hydroxybutyrate or urine ketones would be critical to determine fetal 
safety of this therapy.  
Exercise  
 Although concern has been expressed about increasing uterine 
contractility, IUGR, prematurity, fetal bradycardia, and ketonuria in 
association with exercise, physically active, well-conditioned women 
have routinely engaged in exercise during pregnancy without apparent 
adversity.  
 Moreover, cardiovascular fitness training outside of pregnancy is known 
to increase insulin sensitivity and glucose disposal by recruitment of 
glucose transporter proteins, thus making exercise an attractive 
therapeutic possibility in GDM.   
 Studies using arm ergometry   or a recumbent bicycle   found moderate 
exercise to be safe and effective in reducing fasting and postprandial 
blood glucose levels in women with GDM. Others failed to see better 
glycemic control with the use of moderate exercise.  (87) 
  Encouraging results were reported (fewer babies with macrosomia) in a 
prospective (but not randomized) trial that was designed to limit 
maternal weight gain of obese women with GDM by a combination of 
diet and exercise.   
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 In a comprehensive review, Gavard and Artal concluded that exercise in 
pregnancy “can reduce adverse maternal and fetal morbidities and 
provide long-term benefit.”  (88) 
Intensified Metabolic Management  
 When goals for maternal  glycemia  are not achieved or sustained with 
the lifestyle modifications outlined earlier, or when signs of excessive 
fetal growth are demonstrated, it is generally acknowledged that there is 
need for more intensive metabolic therapy.  
 Operationally, we advise changes in the treatment regimen if more than 
20% to 25% of glucose monitoring values are above fasting/premeal or 
postprandial targets (individually or in combination). 
  Historically, treatment with insulin has been used in such instances, 
since the use of oral medications was specifically “not 
recommended.”  (89) 
   However, on the basis of results from randomized controlled trials, use 
of the oral medication glyburide (glybenclamide outside of the United 
States) is now recognized as being a commonly used alternative to 
therapy with insulin.   
 Results of a clinical trial of GDM treatment with metformin have also 
been published recently.   
 
 
 
55 
 
Insulin  
 The precise place for insulin therapy in GDM remains difficult to define. 
It is generally agreed that a woman with overt hyperglycemia diagnostic 
of DM (FPG ≥ 126 mg/dL [7.0 mmol/L]) should start insulin 
immediately because the perinatal risks are like those for patients with 
preexisting diabetes.  
 Approximately 0.5 to 1.4 units of insulin per kilogram of body weight 
per day is required to maintain fasting/premeal and 1- or 2-hour 
postprandial values within the target ranges defined earlier.  
 A “mixed/split” insulin regimen (rapid-acting [human regular insulin or 
analogue]/intermediate-acting [NPH) has typically been used for many 
years, although multiple daily injections may provide greater flexibility 
in management.  (90) 
 As noted, during pregnancy, as well as outside of pregnancy, the rapid-
acting insulin analogues have an established place in management of 
preexisting diabetes and are now commonly used in GDM .Currently the 
use  of long-acting analogues in the treatment of GDM is not 
recommended. 
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ORAL HYPOGLYCEMIC AGENTS 
Metformin  
 Although metformin freely crosses the placenta, use of metformin in 
childbearing women has increased substantially in recent years.  
 It is frequently used to enhance fertility in patients with polycystic 
ovarian syndrome (PCOS).  
 However, there is no compelling evidence that metformin reduces 
pregnancy loss,  (91)  and it is currently recommended that metformin be 
discontinued as soon as pregnancy is confirmed.   
 There is also renewed interest in the use of metformin for the treatment 
of some patients with type 2 DM or GDM.  
 Results of a randomized trial of the use of metformin or insulin for 
treatment of GDM (MIG Trial) in Australia and New Zealand have been 
published.  (92)  No evidence of adverse effects of metformin was found 
on perinatal outcomes  or in a follow-up examination at 2 years of 
age.  (93) 
 However, nearly half of those assigned to the metformin arm required 
the addition of insulin to achieve glycemic treatment targets. 
Furthermore, since metformin freely crosses the placenta, conclusive 
assessment of the safety and benefits of metformin use in pregnancy 
requires long-term follow-up of the offspring. 
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Other Antihyperglycemic Agents  
Safety of thiazolidinedione, α-glucosidase, or dipeptidyl protease-4 (DP4) 
inhibitor therapy in pregnancy has not been examined.  
Other Criteria for Initiating Intensified Therapy  
 Various criteria or algorithms (apart from or in addition to severity of 
maternal hyperglycemia) have been used to identify pregnancies at 
highest risk for fetal hyperinsulinemia or increased size, or both, and to 
serve as criteria for insulin treatment.  
 Weiss and coworkers  (94) used elevated amniotic fluid insulin levels 
(which reflect fetal hyperinsulinemia) to determine the need for insulin 
therapy and reported good fetal outcomes in uncontrolled trials.  
 Fetal ultrasound to measure abdominal circumference    has been used to 
stratify the risk for macrosomia. Those with abdominal circumference 
less than the 75th percentile were not at increased risk. Those with 
abdominal circumference at the 75th percentile or higher were 
considered at risk, and intensive insulin therapy in these patients 
eliminated that risk 
 The long-term outcomes associated with the application of these 
methods must be evaluated further because the risk for obesity and 
glucose intolerance in the offspring is not dependent on the presence 
ofmacrosomia at birth.   
 The hypothesis that a relatively low hemoglobin A  1c concentration can 
identify a subgroup of patients who may be treated by diet therapy alone 
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with no excess risk for fetal complications also warrants further 
investigation.   
Timetable of antenatal appointments 
Maintaining good glycemic control is the key intervention for reducing 
the frequency and/or severity of complications related to gestational diabetes 
mellitus (GDM).  
Glucose monitoring and control — Glycemic control is the 
cornerstone of management of any diabetic pregnancy. Glucose monitoring, 
medical nutritional therapy, exercise, and the use of insulin and anti-
hyperglycemic agents are discussed in detail separately.  
Antenatal fetal testing -  
1) We obtain twice weekly nonstress tests with an amniotic fluid index 
beginning at 32 weeks of gestation in women who need insulin or an 
oral antihyperglycemic agent to achieve good glycemic control. 
2) The evidence supporting antenatal fetal testing in pregnancies 
complicated by GDM consists primarily of data from observational 
series that report no or rare fetal losses among a group of pregnancies 
monitored by various antenatal testing regimens. 
3)  There are no randomized trials evaluating antenatal obstetrical 
management of women with GDM specifically, and findings from the 
small number of cohort and case-control studies are inconclusive. 
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The practice pattern that has evolved is to base use of fetal testing on  
1. The severity of GDM (ie, whether euglycemia is achieved and whether 
it is achieved by nutritional therapy/exercise or by pharmacologic 
therapy) and  
2. The presence of other risk factors for adverse pregnancy outcome (eg, 
advanced maternal age, past history of stillbirth, presence of 
comorbidities such as chronic hypertension). 
3. The timing for initiating testing in the third trimester, the frequency of 
testing, and the tests utilized (eg, nonstress test, biophysical profile 
score) vary by institution and practice setting. 
4. As some studies have reported that women with GDM are at increased 
risk of stillbirth we agree with expert opinion, which generally 
recommends that women who require insulin or an oral 
antihyperglycemic agent to maintain euglycemia or who have poorly 
controlled blood glucose levels should be managed the same way as 
women with pregestational diabetes or other conditions placing the 
pregnancy at increased risk of adverse outcome. 
5. These women typically undergo periodic antenatal testing, usually 
initiated at about 32 weeks of gestation. Although we perform nonstress 
tests with an amniotic fluid index twice per week, there is no strong 
evidence favoring twice weekly testing over weekly testing or initiating 
testing at 32 weeks versus later in gestation. Other medical centers 
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begin nonstress testing weekly at 32 weeks and increase to twice 
weekly at 36 weeks 
6. In contrast, there is some evidence that women who are euglycemic 
with nutritional therapy alone (ie, class A1 GDM) and who have no 
other pregnancy complications (eg, no macrosomia, preeclampsia, 
growth restriction, polyhydramnios or oligohydramnios) are not at 
increased risk of stillbirth therefore, omitting antenatal fetal 
surveillance (nonstress testing or biophysical profile scoring) is a 
reasonable approach for these women, but given the range of existing 
data on this issue, practice varies. 
7. The American College of Obstetricians and Gynecologists (ACOG) has 
suggested antenatal fetal assessment beginning at 32 weeks of gestation 
for women with GDM and poor glycemic control on nutritional therapy 
and for all women treated with insulin or oral agents .  
No specific recommendations were made for fetal assessment in patients 
with well-controlled GDM on nutritional therapy, except for assessment of 
amniotic fluid volume.  
This decision was left to local practice patterns. However, assessment 
can be begun closer to or at term since no increased risk of stillbirth has been 
demonstrated before 40 weeks in this population. 
Assessment of fetal growth 
 We perform a single third trimester ultrasound examination at 36 to 39 
weeks to estimate fetal weight in all women with GDM, regardless of 
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degree of metabolic control or requirement for insulin or oral anti-
hyperglycemic agents. Identification of accelerated fetal growth before 
delivery may be useful to identify maternal-fetal pairs who may benefit 
from scheduled cesarean delivery to avoid trauma from shoulder 
dystocia. 
 Some clinicians also obtain an ultrasound examination early in the third 
trimester to identify fetal growth acceleration as this appears to be a sign 
of nonoptimal glycemic control. Others use the information to identify 
maternal-fetal pairs that may benefit from induction of labor before the 
fetus grows too large.) 
 Unfortunately, there is no method of fetal growth assessment that 
performs well; all current methods are neither particularly sensitive nor 
specific, especially for identifying the large for gestational age (LGA) 
fetus. One review of pregnant women with diabetes treated with insulin 
found that the sonographically estimated fetal weight had to be ≥4800 
grams for there to be at least a 50 percent chance the infant's birthweight 
would be ≥4500 grams.  
 Studies in nondiabetic pregnancies report similar results. Investigators 
have tried to find a more sensitive modality to estimate fetal weight, but 
there is little evidence that these experimental modalities can improve 
on existing two-dimensional ultrasound technology. 
 In view of these limitations, a broad spectrum of practice has evolved, 
ranging from a single ultrasound at 36 weeks of gestation to assess the 
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potential for macrosomia to frequent ultrasounds to monitor fetal growth 
(eg, at 28, 32, and 36 weeks of gestation. Similar to the situation with 
antenatal testing, some providers do not monitor fetal growth 
sonographically in euglycemic women with A1 GDM (medical 
nutritional therapy alone) because of concern that false-positive findings 
will lead to iatrogenic complications. As an example, one study reported 
an increase in cesarean delivery among women who had a third trimester 
ultrasound examination, even after controlling for birthweight . 
Timing of delivery — One of the key issues of the management of women 
with GDM is whether to induce labor and, if so, when? 
 The major potential benefits of induction are avoidance of late stillbirth 
and avoidance of delivery-related complications of continued fetal 
growth, such as shoulder dystocia or cesarean delivery.  
 The potential disadvantages include the risks of induction (eg, longer 
labor, neonatal morbidity in deliveries <39 weeks).  
 The optimal timing of delivery in GDM has not been evaluated in well-
designed trials; the available data  are inadequate to allow a strong 
evidence-based recommendation.  
 However, increasing evidence suggests that induction of labor does not 
consistently lead to higher cesarean delivery rates than expectant 
management (95) 
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A1 GDM  
 Our approach, and the practice pattern that has evolved in many 
institutions, is to manage pregnancies of women who remain euglycemic 
with nutritional therapy and exercise alone (A1 GDM) by beginning a 
discussion about the possibility of induction of labor when the woman 
reaches her estimated date of delivery, 40+0 weeks of gestation, and 
recommending induction when she reaches 41+0 weeks of gestation; 
 Induction of labor at this gestational age reduces the risks associated 
with postterm pregnancy .This relatively noninterventional approach is 
based on the favorable outcomes reported in a classic uncontrolled case 
series of 196 women with Class A diabetes managed this way (96). 
 Although clinical practice varies from institution to institution, there is 
generally consensus that these patients should not be electively delivered 
prior to 39 weeks of gestation (97). However, subsequent management is 
less clear; delaying intervention until after 40 weeks may increase the 
risk of cesarean delivery (98) 
While a decision analysis found that fetal and neonatal mortality may be 
minimized by delivery at 38 weeks of gestation, this mathematical model alone 
is insufficient for changing our clinical practice . ACOG has opined that 
delivery should not be planned before 39 weeks of gestation unless otherwise 
indicated, and that expectant management up to 40+6 weeks is generally 
appropriate with antepartum testing (99)100). 
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A2 GDM — 
For women with GDM whose glucose levels are medically managed 
with insulin or oral agents (A2 GDM), we recommend induction of labor at 39 
weeks of gestation based on data from a retrospective cohort study of women 
with GDM indicating that the infant mortality rate at 39 weeks 
(8.7/10,000) was statistically lower than the risk of stillbirth plus infant 
mortality with expectant management over an additional week (15.2/10,000)  
 In addition, induction may reduce the risk of shoulder dystocia 
compared to later delivery (101)(102). Early term delivery (37 or 38 weeks) 
is not indicated in uncomplicated A2 GDM with well-controlled glucose 
levels as the risk of stillbirth is low while neonatal morbidity rates are 
increased at this gestational age (103); however, if a concomitant medical 
condition (eg, hypertension) is present or glycemic control is 
suboptimal, delivery should be undertaken as clinically indicated prior 
to 39 weeks of gestation [101). Fetal weight also needs to be considered.  
ACOG suggests delivery at 39+0 to 39+6 weeks of gestation for women with 
GDM well controlled with medication(104). However, guidance for women with 
poor glycemic control is less precise. They suggest that delivery at 37+0 to 
38+6 weeks of gestation may be reasonable, but that delivery prior to 37+0 
weeks should only be done when more aggressive efforts to control blood 
sugars, such as hospitalization, have failed. 
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 Scheduled cesarean delivery — Scheduled cesarean delivery to avoid 
birth trauma is typically offered to women with GDM and estimated 
fetal weight ≥4500 grams.  
 The fetal weight threshold at which scheduled cesarean delivery should 
be performed to reduce the risk of birth trauma from shoulder dystocia is 
controversial.  
 It has been estimated that in diabetic pregnancies with an estimated fetal 
weight of ≥4500 grams, 443 cesareans would need to be performed to 
prevent one permanent brachial plexus injury  
 .Whether this trade-off justifies the increased risks of cesarean delivery 
is unclear.  
 The ACOG practice bulletin on GDM recommends discussing the risks 
and benefits of scheduled cesarean delivery with women with GDM and 
estimated fetal weight ≥4500 grams (104).  
When counseling patients, key issues to address include:  
(1) The difficulty in accurately predicting birthweight by any method,  
(2) The risks of a cesarean delivery in the current pregnancy, and  
(3) The risks of a prior cesarean delivery on management and outcome of 
future pregnancies.  
If a woman with estimated fetal weight ≥4500 grams decides to undergo 
a trial of labor, we follow labor progress closely and perform an operative 
vaginal delivery only if the fetal vertex has descended normally in the second 
stage of labor because instrumental delivery is associated with a higher risk of 
66 
 
shoulder dystocia and brachial plexus injury, and the risk is even higher with 
the use of vacuum as compared with forceps. 
Labor and delivery 
 During labor, periodic assessment of maternal glucose levels and 
treatment of hyperglycemia is prudent, although intrapartum maternal 
hyperglycemia leading to an adverse neonatal outcome is infrequent in 
GDM . 
 The goal of treatment is to reduce the risk of neonatal hypoglycemia. 
Although prolonged neonatal hypoglycemia is primarily due to fetal 
exposure to chronic hyperglycemia during pregnancy and resultant fetal 
pancreatic hyperplasia, transient hypoglycemia can be caused by 
intrapartum maternal hyperglycemia, which induces an acute rise in fetal 
insulin  
 Insulin requirements usually decrease during labor, as the work of labor, 
particularly uterine contractions, requires energy and oral caloric intake 
is typically reduced. 
 Women with GDM who were euglycemic without use of insulin or oral 
antihyperglycemic drugs during pregnancy do not normally require 
insulin during labor and delivery, and thus do not need their blood 
glucose levels checked hourly. 
 Women with GDM who used insulin or oral antihyperglycemic drugs to 
maintain euglycemia occasionally need insulin during labor and delivery 
to maintain euglycemia.  
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 There is no consensus about optimal glycemic control during labor and 
delivery. In one survey of academic medical centers, 60 percent of 
respondents reported their target intrapartum blood glucose level was 
<110 mg/dL (6.1 mmol/L) and 30 percent reported a target between 110 
and 150 mg/dL (6.1 and 8.3 mmol/L) (105).  
 The Endocrine Society suggests target glucose levels of 72 to 
126 mg/dL (4.0 to 7.0 mmol/L) (106) 
 We generally check blood glucose measurements every two hours 
during labor and begin intravenous insulin at glucose levels above 
120 mg/dL (6.7 mmol/L). We prefer this approach because mild 
hyperglycemia is generally less morbid and easier to treat than 
intrapartum hypoglycemia, which may occur when a long-acting insulin 
is administered subcutaneously 
For women undergoing scheduled cesarean delivery, insulin or 
antihyperglycemic drugs are withheld the morning of surgery and the woman is 
not allowed any oral in 
POSTPARTUM MANAGEMENT AND FOLLOW-UP:  
Women with gestational diabetes mellitus (GDM) should be able to 
resume a normal diet postpartum. After delivery, the hyperglycemic effects of 
placental hormones dissipate rapidly. Thus, most women revert back to their 
prepregnancy glycemic status almost immediately. 
However, since some women with GDM may have previously 
unrecognized type 2 diabetes mellitus, we agree with Endocrine Society 
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recommendations to check glucose concentrations for 24 to 72 hours after 
delivery to exclude ongoing hyperglycemia(106). The algorithm for postpartum 
surveillance that was recommended by the Fifth International Workshop 
Conference on Gestational Diabetes Mellitus    is outlined in  the below table.  
-fasting glucose concentrations suggest overt diabetes (fasting glucose 
≥126 mg/dL [7 mmol/L] orrandom glucose ≥200 mg/dL [11.1 mmol/L]), 
treatment is warranted; the type of treatment (weight reduction, diet, exercise, 
medication) should be decided on a case-by-case basis, often with consultation 
from an endocrinologist. 
 Women who have fasting glucose levels below 
126 mg/dL (7 mmol/L) after delivery should have a two-hour 75-gram 
oral glucose tolerance test 6 to 12 weeks postpartum to test for diabetes 
or prediabetes. 
 Women with diabetes are managed, as medically Women with 
prediabetes or a normal glucose tolerance test are counseled about their 
future risk of diabetes, as well as preventive interventions and follow-up 
(rescreening interval). 
Contraception: While any type of contraception is acceptable, as long as the 
usual medical contraindications to use are absent, we recommend long-acting 
reversible contraception (LARC) (eg, intrauterine device, contraceptive 
implant) because of the minimal risk of unplanned pregnancy with these 
methods (107) There is no convincing evidence that hormonal contraceptives 
(estrogen-progestin or progestin-only) increase the user’s risk of developing 
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diabetes . Choosing contraceptives with lower systemic hormone levels in 
theory should minimize any changes in metabolic parameters. If a patient is 
concerned about hormonal issues, a copper-releasing IUD is a good alternative. 
TABLE 11 
Metabolic Assessments After Gestational Diabetes Mellitus  ∗  
Time  Test  Purpose  
Postdelivery (1-3 days)  Fasting or random 
plasma glucose  
Detect persistent, overt 
diabetes  
Early postpartum (around time 
of the “postpartum visit”)  
75-g 2-hour 
OGTT  
Postpartum classification 
of glucose metabolism  
1 year postpartum  75-g 2-hour 
OGTT  
Assess glucose 
metabolism  
Annually  Fasting plasma 
glucose  
Assess glucose 
metabolism  
Triannually  75-g 2-hour 
OGTT  
Assess glucose 
metabolism  
Prepregnancy  75-g 2-hour 
OGTT  
Classify glucose 
metabolism  
  
OGTT,  Oral glucose tolerance test.  
Data from Metzger BE, Buchanan TA, Coustan DR, et al. Summary and 
recommendations of the Fifth International Workshop Conference on 
Gestational Diabetes Mellitus.  Diabetes Care  . 2007;30(Suppl 2), p. S258.  
∗ Glucose metabolism classified by criteria recommended by the American 
Diabetes Association  12  .  
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MATERIALS AND METHODS 
This was a cross sectional study performed on 200 antenatal women in 
their second and third trimesters of pregnancy from 20 weeks of gestational age 
till term..100  women with gestational diabetes mellitus and 100 women with 
healthy pregnancies were enrolled into the study . 
SAMPLE SIZE -100 cases and 100 controls 
Women enrolled under the study were divided into cases and controls. 
 Case group includes women with recently diagnosed gestational 
diabetes mellitus diagnosed using a one step 2 hr OGTT as per the 
guidelines proposed by American diabetes Association. 
The cut off values were taken as per the Carpenter and couston  
 Control group includes women with healthy pregnancies beyond 20 wks 
of gestational age till term   and with a normal Glucose tolerance  test . 
 
PLACE OF STUDY- The study was conducted at the outpatient department of 
obstetrics and Gynaecology, Madras medical college, Chennai 
DURATION OF STUDY- This cross   sectional study was conducted over a 
period of one year . 
INCLUSION CRITERIA 
-All women recently diagnosed with gestational diabetes mellitus (gestational 
age ranging from 20 weeks to term )who have had normal pregnancies before . 
-All healthy pregnancies from 20 weeks  gestational age to term   
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EXCLUSION CRITERIA 
 Women with systemic diseases (hypertension ,collagen tissue disease 
,heart disease ,renal disease ,hepatic disease ,immune thrombocytopenic 
purpura ,bone marrow disorders ) 
 Women with poor obstetric history requiring medication during 
gestation(recurrent pregnancy loss) 
 Previous occurance of preeclampsia ,preterm labour ,intrauterine growth 
restriction or Intrauterine foetal demise . 
 
DATA COLLECTION AND METHODS 
o After obtaining  a written informed consent patients were enrolled into 
the study . 
o Basic demographic details like Age,socioeconomic status,residential 
area,educational status were collected using a standard questionnaire. 
o Obstetric details like gravidity,parity,previous history of 
abortion,maternal height ,weight and comorbid medical conditions were 
collected . 
o Patients were categorized into the control group and test group 
depending on the OGTT value. 
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MATERIAL AND METHODS 
To avoid the platelet swelling induced by ethylene diamine tetra acetate 
(EDTA), blood samples were analyzed within half an hour of collection. An 
automated blood counter was used to measure complete blood count (CBC) 
parameters. 
STATISTICAL ANALYSIS 
Nonparametric tests were chosen for comparison due to the relatively small 
sample size.  
The Mann-Whitney test, student’s t test, and Spearman correlation analysis 
were utilized when appropriate. p<0.05 was regarded as significant. 
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Table 12 
AGE DISTRIBUTION IN CONTROL GROUP 
 
 CONTROL 
<20 YEARS Count  4 
 Percentage  4 % 
 
20-25 YEARS 
 
Count 35 
% within GROUP 35.0% 
26-30 YEARS Count  
30 
% within GROUP 30.0% 
 
31-35 YEARS Count  
28 
% within GROUP 28.0% 
 
>35  YEARS  
Count   
3 
 % within GROUP 3% 
TOTAL Count 100 
% within GROUP 100.0% 
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TABLE 13 
AGE DISTRIBUTION IN TEST GROUP 
 
 TEST 
< 20 YEARS Count 
Percentage 
2 
2% 
20-25 YEARS Count 26 
% within GROUP 26.0% 
26-30 YEARS Count 33 
% within GROUP 33.0% 
 
31-35 YEARS Count 35 
% within GROUP 35.0% 
>30 YEARS Count 
% within GROUP 
4 
4% 
Total Count 100 
% within GROUP 100.0% 
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TABLE 14 
 
 
DISTRIBUTION OF AGE GROUP IN HEALTHY VERSUS GDM 
PREGNANCIES 
 GROUP 
TEST HEALTHY 
AGE 
GOUP 
<20 YRS  
 
 
 
20-25 
YEARS 
Count 
Percentage  
Count 
2 
2% 
  26 
4 
4% 
35 
Percentage 26.0% 35.0% 
26-30 
YEARS 
Count 
Percentage 
33 30 
 33.0% 
 
30.0% 
31-35 
YEARS 
>35 YEARS 
 
Count 
Percentage 
35 28 
Count 
Percentage 
35.0% 
4 
4% 
28.0% 
3 
3% 
Total Count 100 100 
 100.0% 100.0% 
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AGE DISTRIBUTION IN TEST AND CONTROL GROUP 
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TABLE 15 
 
MEAN AGE BETWEEN TEST GROUP AND CONTROL GROUP 
 
 
 
GROUP N Mean Std. Deviation Std. Error 
Mean 
AGE 
TEST 100 30.3800 4.66619 .46662 
CONTROL 100 27.67800 4.67699 .46891 
 
 
 
 
 
 
 
 
 
 
 
 
 
30.38 27.67
0
5
10
15
20
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30
TEST CONTROL
MEAN AGE IN HEALTHY AND TEST GROUP 
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TABLE 16 
DISTRIBUTION OF CASES IN CONTROL GROUP AS PER PARITY  
 
 
 CONTROL 
GRAVIDA 
PRIMI 
Count 38 
% within GROUP 38.0% 
G2 
Count 36 
% within GROUP 36.0% 
G3 
Count 21 
% within GROUP 21.0% 
G4 
Count 4 
% within GROUP 4.0% 
G5 
Count 1 
% within GROUP 1.0% 
Total 
Count 100 
% within GROUP 100.0% 
 
 
TABLE 17 
DISTRIBUTION OF CASES IN TEST GROUP AS PER PARITY 
 
 TEST 
GRAVIDITY 
PRIMI 
Count 15 
% within GROUP 15.0% 
G2 
Count 35 
% within GROUP 35.0% 
G3 
Count 41 
% within GROUP 41.0% 
G4 
Count 6 
% within GROUP 6.0% 
G5 
Count   3 
% within the group    3 % 
Total 
Count 100 
% within GROUP 100.0% 
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COMPARISON OF BOTH GROUPS WITH PARITY AS  A FACTOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
HEALTHY TEST
PRIMI G2 G3 G4 G5 Column1
35%
15%
41%
6%
3%
38%
36%
21%
4%
1%
 
82 
 
 
 
TABLE 18 
MEAN BLOOD GLUCOSE VALUE IN BOTH GROUPS 
 
 
 
 GROUP N Mean Std. 
Deviation 
Std. 
Error 
Mean 
Independent 
Samples Test 
BLOOD_ 
SUGAR 
TEST 100 117.32 36.97 3.70 7.222** 
CONTROL 100 85.14 24.87 2.49 
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COMPARISON OF MEAN BLOOD SUGAR VALUE IN TEST AND 
CONTROL GROUP 
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TABLE 19 
HBA1C IN HEALTHY AND TEST GROUP 
 
 
GROUP N Mean Std. 
Deviation 
Std. 
Error 
Mean 
Independent 
Samples Test 
HBA1C 
TEST 100 5.76 1.22 0.12 
7.560** 
CONTROL 100 4.66 0.80 0.08 
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TABLE 20 
 
COMPARISON OF VARIOUS BLOOD INDICES BETWEEN 
HEALTHY AND TEST GROUP 
 
 
Group Statistics     
GROUP N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
 Independ
ent ‘t’ 
Test 
VALUE 
 P 
VALUE 
BMI TEST 100 28.14 2.97 0.30 10.438** P<0.001 
CONTROL 100 23.92 2.74 0.27 
LEUKOCYTE  
COUNT 
TEST 100 8.80 2.36 0.24 1.99 0.048 
CONTROL 100 8.13 2.40 0.24 
HBA1C TEST 100 5.76 1.22 0.12 7.560** P<0.001 
CONTROL 100 4.66 0.80 0.08 
HAEMATO 
CRIT 
TEST 100 34.86 4.20 0.42 2.388* 0.018 
CONTROL 100 33.50 3.83 0.38 
PLATELET 
COUNT 
TEST 100 2.48 0.76 0.08 0.784 0.435 
CONTROL 100 2.56 0.68 
0.07 
MEAN  
PLATELET 
VOLUME 
TEST 100 11.13 2.40 0.24 9.496* p<0.001 
CONTROL 100 7.77 2.6 
0.26 
PLATELET 
DISTRIBUTION 
WIDTH  
TEST 100 18.28 1.51 0.15 0.874 0.384 
CONTROL 100 18.1 1.4 
0.14 
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TABLE 21 
 
CORELATION OF VARIOUS CLINICAL PARAMETERS WITH 
BLOOD GLUCOSE LEVEL 
 
 
CORRELATION FOR ALL 200 
SAMPLES(CONTROL +TEST) 
BLOOD_SUGAR 
BMI 
Pearson Correlation .898** 
Sig. (2-tailed) .000 
N 200 
LEUKOCYTE_COUNT 
Pearson Correlation .325** 
Sig. (2-tailed) .000 
N 200 
HBA1C 
Pearson Correlation .915** 
Sig. (2-tailed) .000 
N 200 
HCT 
Pearson Correlation .835** 
Sig. (2-tailed) .000 
N 200 
PLT_COUNT 
Pearson Correlation .431** 
Sig. (2-tailed) .000 
N 200 
MPV 
Pearson Correlation .853** 
Sig. (2-tailed) .000 
N 200 
PDW 
Pearson Correlation .171* 
Sig. (2-tailed) .015 
N 200 
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TABLE 22 
 
CORRELATION FOR  TEST SAMPLES 100 BLOOD_SUGAR 
BMI 
Pearson Correlation .925** 
Sig. (2-tailed) .000 
N 100 
LEUKOCYTE_COUNT 
Pearson Correlation .113 
Sig. (2-tailed) .261 
N 100 
HBA1C 
Pearson Correlation .921** 
Sig. (2-tailed) .000 
N 100 
HCT 
Pearson Correlation .904** 
Sig. (2-tailed) .000 
N 100 
PLT_COUNT 
Pearson Correlation .925** 
Sig. (2-tailed) .000 
N 100 
MPV 
Pearson Correlation .923** 
Sig. (2-tailed) .000 
N 100 
PDW 
Pearson Correlation .120 
Sig. (2-tailed) .233 
N 100 
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TABLE 23 
 
 
CORRELATION FOR  CONTROL  SAMPLES 100 BLOOD_SUGAR 
BMI 
Pearson Correlation .824** 
Sig. (2-tailed) .000 
N 100 
LEUKOCYTE_COUNT 
Pearson Correlation .581** 
Sig. (2-tailed) .000 
N 100 
HBA1C 
Pearson Correlation .828** 
Sig. (2-tailed) .000 
N 100 
HCT 
Pearson Correlation .825** 
Sig. (2-tailed) .000 
N 100 
PLT_COUNT 
Pearson Correlation -.149 
Sig. (2-tailed) .140 
N 100 
MPV 
Pearson Correlation .824** 
Sig. (2-tailed) .000 
N 100 
PDW 
Pearson Correlation .309** 
Sig. (2-tailed) .002 
N 100 
 
 
 In the control group the percentage of patients belonging to <20 yrs was 
4%..The number of patients belonging to 20-25 , 26-30 and  31-35 age 
group were 35%,  30% and 28%respectively . 3% of patients in the 
control group were >35 yrs. 
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  Similarly in the test group 2 % of patients were <20 yrs old, 26% of 
patients belonged to 20-25 age group,33% were in 26-30 age group , 
35% belonged to 30-35 yrs and 4% of patients were >35 yrs old . 
 The mean age in control group was 27.67 whereas in the test group the 
mean age was 30.38. 
 With respect to parity status majority of the patients 38% in control 
group were Primigravida. In the test group majority of the patients 41% 
were G3. 
 Mean blood glucose value in test group and control group were 117.32 
and 85.14 respectively. 
 Mean BMI in control group was 28   whereas the mean BMI of test 
group was  23.The difference was statistically significant at a p value of 
0.001. 
 Mean HBA1C in healthy  group was 4.7 whereas in the GDM group it 
was 5.7 .The difference was statistically significant at a p value of 0.001. 
 MPV mean in healthy group was 7.7 fl whereas in test group the MPV 
was 11.13 fl. The group with gestational diabetes mellitus had a 
statistically significant higher value of mean platelet volume (p= 0.001). 
 The average  platelet count was marginally higher in the test group but 
the difference in mean was not statistically significant . 
 The mean value of platelet distribution width between the test and the 
control group was similar.  
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 Correlation between mean glucose values against various clinical 
parameters like BMI,HbA1C,Haematocrit,Leukocyte count, Mean 
platelet volume,Platelet count and platelet distribution width was done 
and is shown in the table.The mean glucose values were linearly 
correlated with HbA1C& BMI with a correlation coefficient of 0.9 
which was statistically significant. Linear correlation was found between 
the mean platelet volume value and blood glucose levels in both test and 
control group with a   pearson  correlation coefficient of 0.923 and 0.824 
respectively  which was statistically significant .There was no 
statistically significant linear correlation between  platelet count and 
blood glucose.There was no correlation between PDW and blood 
glucose levels. 
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DISCUSSION 
Altered platelet morphology and function have been reported in patients 
with diabetes (106). Patients with diabetes have increased platelet activation 
compared to nondiabetic subjects (108)(109) 
 Platelet hyperactivity is accompanied by increased synthesis of 
thromboxane and/or decreased prostacycline production. MPV is a 
marker of platelet function and activation (110).  
 Larger platelets are both more reactive and aggregable. They contain 
denser granules, secrete more serotonin and b-thromboglobulin, and 
produce more thromboxane A2 than smaller platelets.  
This points to a relationship between platelet function and micro- and 
macrovascular complications of diabetes mellitus (DM) (111). 
 Recently, an increase in MPV in the late phase of myocardial infarction 
has been shown to be an independent predictor for recurrent myocardial 
infarction  
 Platelet hyperactivity in DM may be a contributor to severe and 
profound vasculopathies associated with this disorder (108). Increased 
platelet aggregation has been demonstrated in DM, and this may 
potentially have a role in the development of vascular complications . 
 Activated platelets respond to activated leukocytes and endothelial cells 
via adhesion molecules linking inflammation and thrombosis  
 Platelets of recent-onset Type 1 diabetic patients have been shown to be 
activated independently of metabolic control  
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 Platelet volume is a marker of platelet activation and function and is 
measured using the MPV (112). MPV values can be an effective marker 
for blood glucose   
 MPV values were found to be higher. However, after the blood glucose 
was reduced, there was a significant decrease in these MPV values 
(108)(112). 
  MPV values have been found to be higher in diabetic patients when 
compared with normal controls (110). 
 Patients with retinopathy and microalbuminuria had higher MPV values 
than patients without diabetic complications  
  In previous studies, MPV was observed to be higher in nonpregnant 
diabetics when compared with the normal population (108).  
 Furthermore, in patients with impaired fasting glucose, which is thought 
to be indicative of prediabetes, a high MPV has been noted (111). In 
comparison to normal sized platelets, thrombocytes with high MPV 
values are more reactive (109, 110). This situation may lead to 
vasoconstriction and vein occlusion and a decrease in the concentration 
of prostacylin, resulting in vasoconstriction at the vascular vein level 
(113).  
 It has been argued that an increase in the MPV sets the stage for micro- 
and macrovascular complications in diabetic patients . 
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Increased MPV values have also been reported in various cardiovascular 
diseases . Some studies have found that increased aggregation and 
multiplication functions occur in diabetic patients’ megakaryocyte stem cells . 
The glycoprotein IB molecule, a marker of megakaryocyte stem cells, is found 
more frequently in the cell membrane of platelets with high MPV values in 
diabetic patients  Other studies have argued that the number of peripheral 
platelets may depend on variables such as the platelet production rate and the 
mean platelet survival (109) 
In our study, we found that HbA1c levels were increased in Gestational 
Diabetes . This finding was expected. The identification of a larger MPV in 
Gestational Diabetes  patients suggests that the MPV may be used as a marker 
for follow-up of diabetic patients. Its potential needs to be confirmed in further 
prospective, randomized, controlled studies.  
Recently, Bozkurt et al. (112) claimed that Gestational Diabetes patients 
had higher MPV values than normal control subjects and that patients with high 
MPV values had low platelet counts. 
In our study the Mean platelet volume as well as platelet count were 
increased in the GDM group. It has been reported that platelet survival is 
shorter in diabetic patients ( 111).  
This may be explained by variables such as platelet production and 
mean platelet survival. The platelet distribution width displays a good 
correlation with the MPV.  
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However we did not detect a significant difference between the platelet 
distribution width values between the two groups. 
Gestational DM is a systemic disease that affects both the mother and 
fetus (1. These patients are more likely to develop Type 2 DM; hence, they 
must be monitored closely. As an increased MPV may reflect increased platelet 
activation, further studies on platelet parameters and functions might be helpful 
in decreasing the mortality and the morbidity associated with Gestational   
Diabetes.  
Gestational Diabetes Mellitus  may not always constitute a good model 
for extrapolation of results to Type 2 diabetes.  However,    modifications in 
glycemia undetectable by standard clinical laboratory methods can be reflected 
via alterations in platelet features. We also compared the influences of short-
term (gestational) diabetes on platelet parameters of CBC. 
DM is associated with serious potential systemic and metabolic risks 
during pregnancy. Diabetic pregnancies   need to be closely observed during 
their antenatal checkups. Close observation is essential to prevent 
complications of diabetic illnesses associated with hyperglycemia, which has a 
negative influence on all maternal systems and on fetal homeostasis. Further 
research may indicate higher MPV values in pregnancies with poor diabetic 
control.  
As studies related to platelet functions in diabetic pregnancies increase, 
we strongly believe that improvements will occur in prenatal and postnatal 
observation and treatment, which will subsequently result in a decrease in 
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fetomaternal complications. 
In the present study, in spite of the fact that MPV was  higher in diabetic 
women than  euglycemic women, however, did not show significant value for 
predicting gestational diabetes mellitus.  
In in a study by Piazze et al. [114], both platelet count and MPV showed 
a relationship with pre-eclampsia. They reported lower platelet count and 
higher MPV in the cases of pregnancy induced hypertension (PIH) and pre-
eclampsia, MPV was reported higher in pregnant women with an abnormal 
uterine artery Doppler, who were affected by diabetes and pre-eclampsia later 
in their pregnancies [115], but platelet count did not show differences between 
these two groups. 
The result of this study is in agreement with the study by Piazza et al. 
[116], which showed that between different parameters of; red blood cell 
(RBC) count, mean corpuscular volume (MCV), hemoglobin (Hb), homatocrit 
(HCT), white blood cell (WBC), platelet count and MPV; only MPV and 
Platelet count was higher in women with gestational diabetes mellitus . The 
other parameters did not have any significant difference 
These researchers concluded that periodic monitoring of MPV plus 
uterine Doppler Velocimetry, might be used in order to improve pregnancy 
management [117]. 
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SCOPE FOR FURTHER RESEARCH 
Inflammatory markers such as C-reactive protein (CRP) and tumor 
necrosis factor-alpha (TNF-α) have been linked to obesity and have been used 
to predict diabetes in non-pregnant subjects. CRP has been linked to high BMI, 
but has not been shown to be an independent predictor for GDM.  While 
placental TNF-α potentiates insulin resistance, studies have not shown a 
connection between TNF-α and GDM. 
First trimester elevations in adipokines, proteins released by adipocytes, 
have been associated with GDM. Adiponectin enhances insulin sensitivity, so 
decreased levels may be a marker for GDM, while leptin, which acts as a 
centrally acting appetite suppressant and peripherally promotes insulin effects, 
has been shown to be elevated in patients who go on to develop GDM. An 
earlier study has suggested that adiponectin may be a useful tool in improving 
prediction of risk, however, the strength of evidence for leptin is not as strong. 
Placenta-derived markers include follistatin-like-3 (FSTL3), placental 
growth factor (PLGF), and placental exosomes, have all been looked at as 
predictor markers for GDM, with FSTL3 having an inverse relationship, and 
PLGF and exosomes displaying a direct relationship in patients with GDM. 
However, a lack of standardized tests for FSTL3, discrepancies in predictive 
ability of PLGF, and the early state of research into placental exosomes render 
these as unfavorable markers at present. 
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Other unique biomarkers are currently being investigated. Glycosylated 
fibronectin has shown promise in one mid-sized study as an independent 
predictor, and a newer prospective study is currently under way.  Another study 
looking at (pro)renin receptor levels showed increased levels in women who 
developed GDM. However, there was significant overlap with levels displayed 
in women who maintained normal glucose status. 
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CONCLUSION 
 At the present time, pregnancy is considered as a condition, which can 
reveal the probability of future metabolic syndrome occurrence and its 
cardiovascular effects  
 As far as it is already concerned, MPV is considered as a valuable and 
early predictor of ischemic stroke prognosis and cardiovascular risks 
  .Unfortunately, there are not many cohort studies on the diagnostic 
value of MPV for predicting gestational diabetes mellitus.  
 Performed studies have been conducted as case–control studies, and 
have shown some controversies which seem to indicate that more 
studies should be performed in order to reach a definite conclusion on 
the role of MPV for predicting gestational diabetes mellitus. 
  It seems that MPV is higher in women who eventually would be 
diabetic but the predictive value of this parameter warrants further 
cohort study. 
 Measurement of the MPV and other platelet-related parameters is a 
simple procedure, available in most hospital laboratories. Platelet-related 
indices and their determination are inexpensive and routinely ordered 
markers, the significance of which is often ignored.  
 They may be useful in screening for gestational diabetes as an adjunct to 
oral glucose tolerance test.  
 These parameters may significantly aid the identification of diabetic 
pregnancies   at risk for vascular complications. 
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 These parameters can also be used as an adjunct to monitor the disease 
after starting treatment since alterations in MPV occur much before 
changes in blood glucose  
  The role of changes in these parameters in the hemostatic system during 
diabetic pregnancy and the possible clinical relevance concerning the 
risk for thrombosis calls  for further studies. 
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ANNEXURES 
  
PROFORMA 
NAME :                   AGE:                                  HOSP NO: 
HEIGHT IN CM-                                        WEIGHT IN Kgs 
GESTATIONAL AGE (IN WEEKS)   
GRAVIDA :             PARITY:            NO OF LIVING CHILDREN:   
 
NO OF ABORTIONS  : 
 
 HISTORY OF PRIOR GDM :  YES/NO 
 
 SIGNIFICANT OBSTETRIC HISTORY  :YES/NO 
 
 HISTORY OF ANY SYSTEMIC ILLNESS   :  YES  /NO 
    HYPERTENSION                                  --            YES  /NO   
                HEART DISEASE                                 --              YES/NO 
                RENAL DISEASE                                 --               YES/NO 
                HAEMATOLOGICAL DISORDER   --              YES/NO 
                BONE MARROW DISORDERS         --              YES/NO 
 
 HISTORY OF CHRONIC MEDICATION INTAKE --    YES/NO 
 
 Screening for GDM done at first trimester      - Yes /No 
 
 OGTT at current visit  -- FBS –   mg/dl 
                                     1 HR OGTT    --  mg/dl 
                                    2  HR  OGTT   -- mg/dl 
     
 BMI             --                                               
 HBA1C        -- 
 HAEMOGRAM RESULTS –               haematocrit— 
                                                                       Leukocyte count  --  x 109 / L 
                                                                       Mean platelet volume  -- fl 
                                                                  Platelet count            --  lakhs / mm3 
                                                                  Platelet distribution width  -- % 
INFORMATION SHEET 
 We are conducting a study on “A COMPARATIVE STUDY OF 
PLATELET PROFILE IN GESTATIONAL DIABETES MELLITUS 
VERSUS HEALTHY PREGNANCIES” over a period of 1 year which is 
very valuable to us.  
 The purpose of this study was to evaluate whether increased mean platelet 
volume is associated with gestational diabetes mellitus patients.   
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared.   
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled.   
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment.   
 
 
Signature of investigator      Signature of participant  
Date:   
  
              PATIENT CONSENT FORM 
 
 
Title: “A COMPARATIVE STUDY OF PLATELET PROFILE IN GESTATIONAL 
DIABETES MELLITUS VERSUS HEALTHY PREGNANCIES” 
 
Name of the Investigator : Dr. T.SHILPA REDDY  
Name of the Participant : 
Name of the Institution : Madras Medical College, Chennai-600 003. 
 
I am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in this study. I was free to ask any questions and they 
have been answered. 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have informed the investigator of all the treatments I am taking or have taken in the past 
    months/years including any native (alternative) treatments. 
6. I have been advised about the risks associated with my participation in the study.* 
7. I have not participated in any research study within the past ____ month(s). * 
8. I am aware of the fact that I can opt out of the study at any time without having to give 
    any reasoned this will not affect my future treatment in this hospital. * 
9. I am also aware that the investigators may terminate my participation in the study at any 
     time, for any reason, without my consent. * 
10. I hereby give permission to the investigators to release the information obtained from me 
      as result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, 
      and IEC if required. 
11. I understand that my identity will be kept confidential if my data are publicly 
      presented. 
12. I have had my questions answered to my satisfaction. 
13. I consent voluntarily to participate in the research/study. 
 
I am aware that if I have any question during this study, I should contact the investigator. By signing 
this consent form, I attest that the information given in this document has been clearly explained to 
me and understood by me. I will be given a copy of this consent document. 
 
 
 
                  
                                                                            
 
                                                                                               Signature/thumb impression of the patient 
 ___________________________________________________ 
 
  
 
 
 
 
 
MASTER CHART 
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 S
U
G
A
R
 
(m
g/
d
l)
B
M
I (
w
t 
in
 k
g 
/ 
h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T
 
(L
ak
h
s 
/ 
m
m
3
)
M
ea
n
 
P
la
te
le
t 
V
o
lu
m
e 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
1
2
0
1
6
9
2
3
.1
5
.1
3
.7
2
8
.4
1
.2
4
5
.1
1
5
.8
2
2
7
2
1
0
8
2
7
.1
9
5
.4
3
3
.5
2
.1
8
8
.3
2
0
.1
3
2
5
1
8
0
2
4
.9
5
.4
4
.4
3
0
.7
1
.6
7
6
.6
1
8
.7
4
3
1
2
1
7
1
3
2
.9
1
2
.9
7
.6
4
0
.7
3
.7
7
1
2
.9
2
0
.2
5
2
4
2
1
5
1
F
5
.8
6
.9
3
8
.4
3
.2
1
1
.4
2
0
.6
6
2
5
2
9
4
2
6
1
1
4
.9
3
2
.1
1
.9
2
7
.4
1
9
.5
7
2
2
1
1
3
4
2
9
.4
1
2
6
.3
3
6
.4
2
.8
4
1
0
.2
2
0
.5
8
2
0
2
1
1
4
2
7
.7
9
.9
5
.6
3
4
.3
2
.3
3
8
.8
1
7
.9
9
3
1
1
1
3
1
2
9
.1
7
.1
6
.2
3
6
.1
2
.7
5
9
.9
1
6
.6
1
0
2
9
1
1
5
1
3
0
.8
6
6
.9
3
8
.2
3
.1
7
1
1
.3
1
6
.7
1
1
3
0
3
7
1
2
4
.1
1
0
.9
4
.1
2
9
.7
1
.4
6
5
.9
1
7
.2
1
2
2
1
1
1
1
4
2
7
.7
6
.2
5
.6
3
4
.3
2
.3
3
8
.8
1
5
.9
1
3
3
0
3
7
7
2
4
.7
8
.1
4
.3
3
0
.5
1
.6
2
6
.4
1
9
.9
1
4
3
2
2
1
6
9
3
2
.6
6
.5
7
.5
4
0
.5
3
.6
6
1
2
.7
1
8
.6
1
5
2
4
3
1
5
1
3
0
.8
9
.7
6
.9
3
8
.2
3
.1
7
1
1
.3
1
9
.4
1
6
2
3
2
9
1
2
5
.6
1
2
.1
4
.8
3
1
.6
1
.8
2
7
.1
2
0
.4
1
7
3
5
1
1
4
0
3
0
1
0
6
.5
3
7
.2
2
.9
6
1
0
.6
1
7
.8
1
8
2
1
3
1
1
4
2
7
.7
8
.2
5
.6
3
4
.3
2
.3
5
8
.8
1
6
.5
1
9
2
8
2
1
2
0
2
8
.1
5
.9
5
.8
3
4
.7
2
.4
2
9
.1
1
8
2
0
3
2
1
1
4
6
3
0
.5
1
0
.8
6
.7
3
7
.8
3
.0
8
1
1
1
6
.8
2
1
2
0
3
6
9
2
3
.2
5
.3
3
.7
2
8
.3
1
.2
4
5
.1
1
8
.8
2
2
3
1
1
1
1
4
2
7
.7
1
1
.8
5
.6
3
4
.3
2
.3
5
8
.8
1
7
.3
2
3
2
2
2
8
2
2
5
.1
7
.3
4
.5
3
0
.8
1
.7
2
6
.7
1
6
2
4
2
3
2
1
6
3
3
2
5
.2
7
.3
3
9
.7
3
.4
5
1
2
.2
1
9
.3
2
5
2
7
3
1
5
7
3
1
.5
1
1
.6
7
.1
3
8
.9
3
.3
2
1
1
.8
1
8
.5
2
6
3
5
3
9
4
2
5
.8
8
.1
4
.9
3
1
.8
1
.8
9
7
.3
1
7
.7
TE
ST
 G
R
O
U
P
 
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 S
U
G
A
R
 
(m
g/
d
c)
B
M
I (
w
t 
in
 k
g 
/ 
h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T
 
(L
ak
h
s 
/ 
m
m
3
)
M
ea
n
 
P
la
te
le
t 
V
o
lu
m
e 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
2
7
2
6
2
1
4
3
3
0
.1
9
.3
6
.6
3
7
.3
3
.0
1
1
0
.7
1
6
.4
2
8
2
7
3
1
1
1
2
7
.5
1
2
.8
5
.5
3
3
.9
2
.2
8
8
.6
1
9
.6
2
9
2
0
2
1
2
3
2
8
.4
5
.7
5
.9
3
4
.9
2
.4
9
9
.3
1
6
.9
3
0
3
5
3
6
0
2
2
.4
9
.4
3
.2
2
5
.5
0
.9
6
4
.2
1
8
.1
3
1
2
9
2
1
4
8
3
0
.7
8
.2
6
.8
3
8
3
.1
5
1
1
.2
1
9
.1
3
2
2
1
1
6
8
2
3
.9
6
.8
4
2
9
.3
1
.4
1
5
.7
1
8
.9
3
3
3
2
4
1
0
3
2
6
.8
1
2
.7
5
.2
3
2
.9
2
.0
9
8
1
7
.4
3
4
2
3
2
7
7
2
4
.6
8
.4
4
.3
3
0
.2
1
.6
6
.3
1
6
.1
3
5
3
4
3
1
6
6
3
2
.2
6
.3
7
.4
4
0
.1
3
.5
1
1
2
.4
1
7
.6
3
6
2
8
1
1
5
4
3
1
.3
1
0
.4
7
3
8
.7
3
.2
7
1
1
.6
1
6
.3
3
7
2
6
4
8
8
2
5
.5
1
1
.7
4
.7
3
1
.3
1
.7
9
7
1
8
.4
3
8
2
9
2
1
4
3
3
0
.1
6
.6
6
.6
3
7
.3
2
.9
9
1
0
.7
1
7
3
9
3
4
4
1
0
5
2
7
8
.3
5
.3
3
3
.3
2
.1
6
8
.2
1
8
.2
4
0
2
9
2
1
2
3
2
8
.5
8
.5
5
.9
3
5
.1
2
.5
2
9
.4
1
9
.8
4
1
2
6
1
1
5
7
3
1
.5
6
.1
7
.1
3
8
.9
3
.3
4
1
1
.8
2
0
4
2
2
8
3
7
1
2
4
.1
7
.3
4
.1
2
9
.7
1
.4
7
5
.9
1
9
.2
4
3
2
2
3
1
1
1
2
7
.5
1
0
.2
5
.5
3
3
.9
2
.2
8
8
.6
1
9
4
4
3
3
1
8
0
2
4
.8
1
1
.6
4
.4
3
0
.6
1
.6
6
6
.5
1
7
.5
4
5
2
4
3
1
6
6
3
2
.3
9
.5
7
.4
4
0
.2
3
.5
7
1
2
.5
1
6
.2
4
6
2
5
2
1
5
4
3
1
.1
1
0
.6
7
3
8
.6
3
.2
4
1
1
.5
2
0
.3
4
7
3
3
3
1
0
3
2
6
.7
7
.4
5
.2
3
2
.7
2
.0
7
7
.9
1
7
.1
4
8
3
0
3
1
4
0
3
0
1
1
.5
6
.5
3
7
.2
2
.9
6
1
0
.6
1
8
.3
4
9
3
4
2
1
1
2
7
.3
7
.2
5
.5
3
3
.8
2
.2
5
8
.5
1
9
.7
5
0
3
3
2
1
8
6
3
3
.9
1
1
.6
8
.1
4
8
.2
3
.9
5
1
3
.9
2
2
.1
5
1
3
3
1
1
8
6
3
3
.9
1
1
.6
8
.1
4
8
.2
3
.9
5
1
3
.9
2
2
.1
5
2
3
4
2
1
1
2
7
.3
7
.2
5
.5
3
3
.8
2
.2
5
8
.5
1
9
.7
5
3
3
0
2
1
4
0
3
0
1
1
.5
6
.5
3
7
.2
2
.9
6
1
0
.6
1
8
.3
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 S
U
G
A
R
 
(m
g/
d
c)
B
M
I (
w
t 
in
 k
g 
/ 
h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T
 
(L
ak
h
s 
/ 
m
m
3
)
M
ea
n
 
P
la
te
le
t 
V
o
lu
m
e 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
5
4
3
3
3
1
0
3
2
6
.7
7
.4
5
.2
3
2
.7
2
.0
7
7
.9
1
7
.1
5
5
2
5
3
1
5
4
3
1
.1
1
0
.6
7
3
8
.6
3
.2
4
1
1
.5
2
0
.3
5
6
2
4
1
1
6
6
3
2
.3
9
.5
7
.4
4
0
.2
3
.5
7
1
2
.5
1
6
.2
5
7
3
3
3
8
0
2
4
.8
1
1
.6
4
.4
3
0
.6
1
.6
6
6
.5
1
7
.5
5
8
2
2
2
1
1
1
2
7
.5
1
0
.2
5
.5
3
3
.9
2
.2
8
8
.6
1
9
5
9
2
8
3
7
1
2
4
.1
7
.3
4
.1
2
9
.7
1
.4
7
5
.9
1
9
.2
6
0
2
6
3
1
5
7
3
1
.5
6
.1
7
.1
3
8
.9
3
.3
4
1
1
.8
2
0
6
1
2
9
2
1
2
3
2
8
.5
8
.5
5
.9
3
5
.1
2
.5
2
9
.4
1
9
.8
6
2
3
4
3
1
0
5
2
7
8
.3
5
.3
3
3
.3
2
.1
6
8
.2
1
8
.2
6
3
2
9
2
1
4
3
3
0
.1
6
.6
6
.6
3
7
.3
2
.9
9
1
0
.7
1
7
6
4
2
6
3
8
8
2
5
.5
1
1
.7
4
.7
3
1
.3
1
.7
9
7
1
8
.4
6
5
2
8
2
1
5
4
3
1
.3
1
0
.4
7
3
8
.7
3
.2
7
1
1
.6
1
6
.3
6
6
3
4
3
1
6
6
3
2
.2
6
.3
7
.4
4
0
.1
3
.5
1
1
2
.4
1
7
.6
6
7
2
3
3
7
7
2
4
.6
8
.4
4
.3
3
0
.2
1
.6
6
.3
1
6
.1
6
8
3
2
3
1
0
3
2
6
.8
1
2
.7
5
.2
3
2
.9
2
.0
9
8
1
7
.4
6
9
2
1
2
6
8
2
3
.9
6
.8
4
2
9
.3
1
.4
1
5
.7
1
8
.9
7
0
2
9
3
1
4
8
3
0
.7
8
.2
6
.8
3
8
3
.1
5
1
1
.2
1
9
.1
7
1
3
5
2
6
0
2
2
.4
9
.4
3
.2
2
5
.5
0
.9
6
4
.2
1
8
.1
7
2
2
0
5
1
2
3
2
8
.4
5
.7
5
.9
3
4
.9
2
.4
9
9
.3
1
6
.9
7
3
2
7
3
1
1
1
2
7
.5
1
2
.8
5
.5
3
3
.9
2
.2
8
8
.6
1
9
.6
7
4
2
6
4
1
4
3
3
0
.1
9
.3
6
.6
3
7
.3
3
.0
1
1
0
.7
1
6
.4
7
5
3
5
3
9
4
2
5
.8
8
.1
4
.9
3
1
.8
1
.8
9
7
.3
1
7
.7
7
6
2
7
2
1
5
7
3
1
.5
1
1
.6
7
.1
3
8
.9
3
.3
2
1
1
.8
1
8
.5
7
7
2
3
5
1
6
3
3
2
5
.2
7
.3
3
9
.7
3
.4
5
1
2
.2
1
9
.3
7
8
2
2
3
8
2
2
5
.1
7
.3
4
.5
3
0
.8
1
.7
2
6
.7
1
6
7
9
3
1
3
1
1
4
2
7
.7
1
1
.8
5
.6
3
4
.3
2
.3
5
8
.8
1
7
.3
8
0
2
0
2
6
9
2
3
.2
5
.3
3
.7
2
8
.3
1
.2
4
5
.1
1
8
.8
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 S
U
G
A
R
 
(m
g/
d
c)
B
M
I (
w
t 
in
 k
g 
/ 
h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T
 
(L
ak
h
s 
/ 
m
m
3
)
M
ea
n
 
P
la
te
le
t 
V
o
lu
m
e 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
8
1
3
2
4
1
4
6
3
0
.5
1
0
.8
6
.7
3
7
.8
3
.0
8
1
1
1
6
.8
8
2
2
8
3
1
2
0
2
8
.1
5
.9
5
.8
3
4
.7
2
.4
2
9
.1
1
8
8
3
2
1
2
1
1
4
2
7
.7
8
.2
5
.6
3
4
.3
2
.3
5
8
.8
1
6
.5
8
4
3
5
3
1
4
0
3
0
1
0
6
.5
3
7
.2
2
.9
6
1
0
.6
1
7
.8
8
5
2
3
3
9
1
2
5
.6
1
2
.1
4
.8
3
1
.6
1
.8
2
7
.1
2
0
.4
8
6
2
4
3
1
5
1
3
0
.8
9
.7
6
.9
3
8
.2
3
.1
7
1
1
.3
1
9
.4
8
7
3
2
2
1
6
9
3
2
.6
6
.5
7
.5
4
0
.5
3
.6
6
1
2
.7
1
8
.6
8
8
3
0
3
7
7
2
4
.7
8
.1
4
.3
3
0
.5
1
.6
2
6
.4
1
9
.9
8
9
2
1
2
1
1
4
2
7
.7
6
.2
5
.6
3
4
.3
2
.3
3
8
.8
1
5
.9
9
0
3
0
3
7
1
2
4
.1
1
0
.9
4
.1
2
9
.7
1
.4
6
5
.9
1
7
.2
9
1
2
9
3
1
5
1
3
0
.8
6
6
.9
3
8
.2
3
.1
7
1
1
.3
1
6
.7
9
2
3
1
4
1
3
1
2
9
.1
7
.1
6
.2
3
6
.1
2
.7
5
9
.9
1
6
.6
9
3
2
0
2
1
1
4
2
7
.7
9
.9
5
.6
3
4
.3
2
.3
3
8
.8
1
7
.9
9
4
2
2
3
1
3
4
2
9
.4
1
2
6
.3
3
6
.4
2
.8
4
1
0
.2
2
0
.5
9
5
2
5
5
9
4
2
6
1
1
4
.9
3
2
.1
1
.9
2
7
.4
1
9
.5
9
6
2
4
2
1
5
1
3
0
.9
5
.8
6
.9
3
8
.4
3
.2
1
1
.4
2
0
.6
9
7
3
1
3
1
7
1
3
2
.9
1
2
.9
7
.6
4
0
.7
3
.7
7
1
2
.9
2
0
.2
9
8
2
5
3
8
0
2
4
.9
5
.4
4
.4
3
0
.7
1
.6
7
6
.6
1
8
.7
9
9
2
7
2
1
0
8
2
7
.1
9
5
.4
3
3
.5
2
.1
8
8
.3
2
0
.1
1
0
0
2
0
3
6
9
2
3
.1
5
.1
3
.7
2
8
.4
1
.2
4
5
.1
1
5
.8
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 
SU
G
A
R
 
(m
g/
d
l)
B
M
I (
w
t 
in
 
kg
 /
 h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T 
(L
ak
h
s 
/ 
m
m
3
)
M
e
an
 
P
la
te
le
t 
V
o
lu
m
e
 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
1
3
3
1
5
3
2
0
4
.6
3
.5
2
7
.9
3
.9
5
3
.8
1
5
.8
2
3
4
1
9
1
2
4
.4
9
.1
4
.8
3
4
.2
2
.2
5
8
.3
2
0
.1
3
3
0
2
5
3
2
0
.2
4
.8
3
.5
2
8
.3
2
.9
6
4
1
8
.7
4
3
3
1
1
1
4
2
6
.9
9
.1
5
.6
3
7
.7
2
.0
7
1
0
.8
2
0
.2
5
2
5
2
7
4
2
2
.3
9
.4
4
.2
3
1
.2
3
.2
4
6
.1
2
0
.6
6
2
4
4
8
2
2
3
.3
5
.7
4
.5
3
2
.8
3
.5
7
7
.2
1
9
.5
7
3
3
2
1
1
1
2
6
.7
1
1
.3
5
.5
3
7
.3
1
.6
6
1
0
.6
2
0
.5
8
2
2
5
1
1
4
2
7
6
.8
5
.6
3
7
.9
2
.2
8
1
0
.9
1
7
.9
9
2
8
1
7
1
2
2
.2
1
1
.6
4
.1
3
1
1
.4
7
6
1
6
.6
1
0
2
6
2
8
2
2
3
.5
8
.2
4
.5
3
3
.1
3
.3
4
7
.4
1
6
.7
1
1
2
9
4
9
4
2
4
.7
9
.4
4
.9
3
4
.6
2
.5
2
8
.6
1
7
.2
1
2
3
4
3
5
3
2
0
.1
4
.7
3
.5
2
8
.1
2
.1
6
3
.9
1
5
.9
1
3
2
9
1
8
8
2
4
8
.7
4
.7
3
3
.7
2
.9
9
7
.9
1
9
.9
1
4
2
6
2
7
1
2
2
6
.6
4
.1
3
0
.7
1
.7
9
5
.8
1
8
.6
1
5
2
8
4
1
4
2
7
.1
1
1
.7
5
.6
3
8
3
.2
7
1
1
1
9
.4
1
6
3
4
4
1
0
5
2
6
.2
8
.4
5
.3
3
6
.8
3
.5
1
1
0
.1
2
0
.4
1
7
2
3
1
8
8
2
4
5
.5
4
.7
3
3
.7
1
.6
7
.9
1
7
.8
1
8
3
2
2
6
9
2
1
.9
9
4
3
0
.5
2
.0
9
5
.7
1
6
.5
1
9
2
1
1
1
1
7
2
7
.2
1
1
.8
5
.7
3
8
.2
1
.4
1
1
1
.1
1
8
2
0
2
9
2
7
8
2
2
.6
7
.2
4
.3
3
1
.7
3
.1
5
6
.4
1
6
.8
2
1
3
5
1
5
5
2
0
.1
6
.7
3
.5
2
8
.2
0
.9
6
3
.9
1
8
.8
2
2
2
0
2
9
7
2
5
6
.5
5
3
5
.1
2
.4
9
8
.9
1
7
.3
2
3
2
7
2
5
6
2
0
.4
5
3
.6
2
8
.5
2
.2
8
4
.2
1
6
2
4
2
6
1
8
5
2
3
.7
1
0
.8
4
.6
3
3
.4
3
.0
1
7
.6
1
9
.3
C
O
N
TR
O
L 
G
R
O
U
P
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 
SU
G
A
R
 
(m
g/
d
l)
B
M
I (
w
t 
in
 
kg
 /
 h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T 
(L
ak
h
s 
/ 
m
m
3
)
M
e
an
 
P
la
te
le
t 
V
o
lu
m
e
 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
2
5
3
5
2
1
0
5
2
6
8
.3
5
.3
3
6
.4
1
.8
9
9
.9
1
8
.5
2
6
2
7
2
1
1
8
2
7
.4
9
.7
5
.7
3
8
.4
3
.3
2
1
1
.3
1
7
.7
2
7
2
3
1
6
6
2
1
.6
4
.6
3
.9
3
0
.1
3
.4
5
5
.4
1
6
.4
2
8
2
2
3
8
9
2
3
.9
6
.3
4
.7
3
3
.6
1
.7
2
7
.8
1
9
.6
2
9
3
1
2
7
4
2
2
.3
9
.4
4
.2
3
1
.2
2
.3
5
6
.1
1
6
.9
3
0
2
0
1
1
1
9
2
7
.5
9
.7
5
.7
3
8
.6
1
.2
4
1
1
.4
1
8
.1
3
1
3
2
3
1
0
7
2
6
.3
1
0
.9
5
.4
3
6
.9
3
.0
8
1
0
.2
1
9
.1
3
2
2
8
2
1
1
1
2
6
.8
7
.1
5
.5
3
7
.6
2
.4
2
1
0
.7
1
8
.9
3
3
2
1
1
1
0
1
2
5
.3
1
0
5
.1
3
5
.5
2
.3
5
9
.2
1
7
.4
3
4
3
5
3
5
9
2
0
.7
5
.3
3
.7
2
8
.9
2
.9
6
4
.5
1
6
.1
3
5
2
3
2
8
2
2
3
.3
8
4
.5
3
2
.8
1
.8
2
7
.2
1
7
.6
3
6
2
4
2
6
4
2
1
.3
5
.9
3
.8
2
9
.7
3
.1
7
5
.1
1
6
.3
3
7
3
2
2
1
2
0
2
7
.6
9
.8
5
.8
3
8
.7
3
.6
6
1
1
.5
1
8
.4
3
8
3
0
1
7
1
2
2
.1
6
.7
4
.1
3
0
.9
1
.6
2
5
.9
1
7
3
9
2
1
3
1
2
0
2
7
.7
1
1
.8
5
.8
3
8
.8
2
.3
3
1
1
.6
1
8
.2
4
0
3
0
2
5
0
1
8
.2
4
.1
3
.3
2
5
.5
1
.4
6
3
.4
1
9
.8
4
1
2
9
1
1
0
7
2
6
.5
1
1
.1
5
.4
3
7
.1
3
.1
7
1
0
.4
2
0
4
2
3
1
3
5
5
2
0
.4
5
3
.6
2
8
.5
2
.7
5
4
.2
1
9
.2
4
3
2
0
3
5
6
2
0
.8
5
.4
3
.7
2
9
.1
2
.3
3
4
.6
1
9
4
4
2
2
1
1
0
4
2
5
.7
1
0
.4
5
.2
3
6
.1
2
.8
4
9
.6
1
7
.5
4
5
2
5
3
6
5
2
1
5
.6
3
.8
2
9
.3
1
.9
2
4
.8
1
6
.2
4
6
2
4
3
8
1
2
2
.9
7
.6
4
.4
3
2
.2
3
.2
6
.8
2
0
.3
4
7
3
1
1
8
2
2
3
.5
8
.2
4
.5
3
3
.1
3
.7
7
7
.4
1
7
.1
4
8
2
5
3
1
2
3
2
7
.9
1
2
.2
5
.9
3
9
.1
1
.6
7
1
1
.8
1
8
.3
4
9
2
7
1
8
5
2
3
.7
8
.4
4
.6
3
3
.4
2
.1
8
7
.6
1
9
.7
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 
SU
G
A
R
 
(m
g/
d
l)
B
M
I (
w
t 
in
 
kg
 /
 h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T 
(L
ak
h
s 
/ 
m
m
3
)
M
e
an
 
P
la
te
le
t 
V
o
lu
m
e
 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
5
0
2
0
2
1
2
8
3
0
.2
1
2
.4
6
.1
4
1
.1
1
.2
4
1
2
.2
2
2
.1
5
1
3
3
2
5
3
2
0
4
.6
3
.5
2
7
.9
3
.9
5
3
.8
1
5
.8
5
2
3
4
1
9
1
2
4
.4
9
.1
4
.8
3
4
.2
2
.2
5
8
.3
2
0
.1
5
3
3
0
3
5
3
2
0
.2
4
.8
3
.5
2
8
.3
2
.9
6
4
1
8
.7
5
4
3
3
1
1
1
4
2
6
.9
9
.1
5
.6
3
7
.7
2
.0
7
1
0
.8
2
0
.2
5
5
2
5
2
7
4
2
2
.3
9
.4
4
.2
3
1
.2
3
.2
4
6
.1
2
0
.6
5
6
2
4
2
8
2
2
3
.3
5
.7
4
.5
3
2
.8
3
.5
7
7
.2
1
9
.5
5
7
3
3
2
1
1
1
2
6
.7
1
1
.3
5
.5
3
7
.3
1
.6
6
1
0
.6
2
0
.5
5
8
2
2
1
1
1
4
2
7
6
.8
5
.6
3
7
.9
2
.2
8
1
0
.9
1
7
.9
5
9
2
8
1
7
1
2
2
.2
1
1
.6
4
.1
3
1
1
.4
7
6
1
6
.6
6
0
2
6
2
8
2
2
3
.5
8
.2
4
.5
3
3
.1
3
.3
4
7
.4
1
6
.7
6
1
2
9
1
9
4
2
4
.7
9
.4
4
.9
3
4
.6
2
.5
2
8
.6
1
7
.2
6
2
3
4
2
5
3
2
0
.1
4
.7
3
.5
2
8
.1
2
.1
6
3
.9
1
5
.9
6
3
2
9
1
8
8
2
4
8
.7
4
.7
3
3
.7
2
.9
9
7
.9
1
9
.9
6
4
2
6
1
7
1
2
2
6
.6
4
.1
3
0
.7
1
.7
9
5
.8
1
8
.6
6
5
2
8
2
1
4
2
7
.1
1
1
.7
5
.6
3
8
3
.2
7
1
1
1
9
.4
6
6
3
4
1
1
0
5
2
6
.2
8
.4
5
.3
3
6
.8
3
.5
1
1
0
.1
2
0
.4
6
7
2
3
2
8
8
2
4
5
.5
4
.7
3
3
.7
1
.6
7
.9
1
7
.8
6
8
3
2
1
6
9
2
1
.9
9
4
3
0
.5
2
.0
9
5
.7
1
6
.5
6
9
2
1
2
1
1
7
2
7
.2
1
1
.8
5
.7
3
8
.2
1
.4
1
1
1
.1
1
8
7
0
2
9
1
7
8
2
2
.6
7
.2
4
.3
3
1
.7
3
.1
5
6
.4
1
6
.8
7
1
3
5
2
5
5
2
0
.1
6
.7
3
.5
2
8
.2
0
.9
6
3
.9
1
8
.8
7
2
2
0
2
9
7
2
5
6
.5
5
3
5
.1
2
.4
9
8
.9
1
7
.3
7
3
2
7
1
5
6
2
0
.4
5
3
.6
2
8
.5
2
.2
8
4
.2
1
6
7
4
2
6
2
8
5
2
3
.7
1
0
.8
4
.6
3
3
.4
3
.0
1
7
.6
1
9
.3
Sl
.N
o
A
G
E 
(Y
EA
R
S)
G
R
A
V
ID
A
B
LO
O
D
 
SU
G
A
R
 
(m
g/
d
l)
B
M
I (
w
t 
in
 
kg
 /
 h
t 
m
t2
)
LE
U
K
O
C
Y
TE
 
C
O
U
N
T 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
X
 x
 1
0
9
 /
 L
H
B
A
1
C
 (
%
)
H
C
T
P
LT
 C
O
U
N
T 
(L
ak
h
s 
/ 
m
m
3
)
M
e
an
 
P
la
te
le
t 
V
o
lu
m
e
 
(M
P
V
) 
fl
P
la
te
le
t 
d
is
tr
ib
u
ti
o
n
 
w
id
th
 (
%
)
7
5
3
5
2
1
0
5
2
6
8
.3
5
.3
3
6
.4
1
.8
9
9
.9
1
8
.5
7
6
2
7
1
1
1
8
2
7
.4
9
.7
5
.7
3
8
.4
3
.3
2
1
1
.3
1
7
.7
7
7
2
3
2
6
6
2
1
.6
4
.6
3
.9
3
0
.1
3
.4
5
5
.4
1
6
.4
7
8
2
2
2
8
9
2
3
.9
6
.3
4
.7
3
3
.6
1
.7
2
7
.8
1
9
.6
7
9
3
1
1
7
4
2
2
.3
9
.4
4
.2
3
1
.2
2
.3
5
6
.1
1
6
.9
8
0
2
0
1
1
1
9
2
7
.5
9
.7
5
.7
3
8
.6
1
.2
4
1
1
.4
1
8
.1
8
1
3
2
2
1
0
7
2
6
.3
1
0
.9
5
.4
3
6
.9
3
.0
8
1
0
.2
1
9
.1
8
2
2
8
1
1
1
1
2
6
.8
7
.1
5
.5
3
7
.6
2
.4
2
1
0
.7
1
8
.9
8
3
2
1
2
1
0
1
2
5
.3
1
0
5
.1
3
5
.5
2
.3
5
9
.2
1
7
.4
8
4
3
5
2
5
9
2
0
.7
5
.3
3
.7
2
8
.9
2
.9
6
4
.5
1
6
.1
8
5
2
3
1
8
2
2
3
.3
8
4
.5
3
2
.8
1
.8
2
7
.2
1
7
.6
8
6
2
4
3
6
4
2
1
.3
5
.9
3
.8
2
9
.7
3
.1
7
5
.1
1
6
.3
8
7
3
2
3
1
2
0
2
7
.6
9
.8
5
.8
3
8
.7
3
.6
6
1
1
.5
1
8
.4
8
8
3
0
1
7
1
2
2
.1
6
.7
4
.1
3
0
.9
1
.6
2
5
.9
1
7
8
9
2
1
3
1
2
0
2
7
.7
1
1
.8
5
.8
3
8
.8
2
.3
3
1
1
.6
1
8
.2
9
0
3
0
3
5
0
1
8
.2
4
.1
3
.3
2
5
.5
1
.4
6
3
.4
1
9
.8
9
1
2
9
1
1
0
7
2
6
.5
1
1
.1
5
.4
3
7
.1
3
.1
7
1
0
.4
2
0
9
2
3
1
1
5
5
2
0
.4
5
3
.6
2
8
.5
2
.7
5
4
.2
1
9
.2
9
3
2
0
3
5
6
2
0
.8
5
.4
3
.7
2
9
.1
2
.3
3
4
.6
1
9
9
4
2
2
1
1
0
4
2
5
.7
1
0
.4
5
.2
3
6
.1
2
.8
4
9
.6
1
7
.5
9
5
2
5
3
6
5
2
1
5
.6
3
.8
2
9
.3
1
.9
2
4
.8
1
6
.2
9
6
2
4
3
8
1
2
2
.9
7
.6
4
.4
3
2
.2
3
.2
6
.8
2
0
.3
9
7
3
1
3
8
2
2
3
.5
8
.2
4
.5
3
3
.1
3
.7
7
7
.4
1
7
.1
9
8
2
5
1
1
2
3
2
7
.9
1
2
.2
5
.9
3
9
.1
1
.6
7
1
1
.8
1
8
.3
9
9
2
7
3
8
5
2
3
.7
8
.4
4
.6
3
3
.4
2
.1
8
7
.6
1
9
.7
1
0
0
2
0
1
1
2
8
3
0
.2
1
2
.4
6
.1
4
1
.1
1
.2
4
1
2
.2
2
2
.1
